Chimeric insect-specific flaviviruses

Abstract

Chimeric proteins that comprise one or more amino acid sequences of an insect-specific flavivirus and one or more other immunogenic proteins are provided. The chimeric proteins are suitably capable of forming virus particles. The chimeric protein and/or virus particle may be suitable for delivery to a subject to elicit an immune response to a pathogen and/or for diagnosis or detection of a pathogen. Also provided are nucleic acids and vectors encoding the chimeric proteins, and isolated chimeric insect-specific flaviviruses comprising the chimeric proteins and/or nucleic acids.

Claims

1. A chimeric flavivirus polyprotein comprising: (i) a polyprotein backbone encoded by the genome of a Lineage II insect-specific flavivirus; and (ii) an immunogenic amino acid sequence of a protein encoded by a genome of a flavivirus that is not insect-specific; wherein the immunogenic amino acid sequence replaces a corresponding amino acid sequence of the polyprotein backbone, and wherein the immunogenic amino acid sequence is selected from the group consisting of: a) a prM protein; b) an Envelope protein, or one or more of an EDI, EDIT, and EDIII domain thereof, and c) a combination of a) and b).

2. The chimeric flavivirus polyprotein of claim 1, wherein the insect-specific flavivirus of (i) is capable of infecting a plurality of different insects.

3. The chimeric flavivirus polyprotein isolated protein of claim 1, wherein the insect-specific flavivirus of (i) is selected from the group consisting of Binjari virus (BinJV); Lilly Creek Virus (LiCV); Ilomantsi virus (ILOV); Donggang virus (DONV); Marisma mosquito virus (MMV); Chaoyang virus (CHAOV); Lammi virus (LAMV); Barkedji virus (BJV); Nhumirim virus (NHUV); Nounané virus (NOUV); and Nanay virus (NANV).

4. The chimeric flavivirus polyprotein of claim 1, wherein the immunogenic amino acid sequence (ii) is of a protein encoded by the genome of a vertebrate-infecting flavivirus.

5. The chimeric flavivirus polyprotein of claim 1, wherein the immunogenic sequence (ii) is of a protein encoded by the genome of a flavivirus selected from the group consisting of Zika virus; West Nile virus; Dengue virus; Japanese encephalitis virus; Yellow fever virus; tick-borne encephalitis virus; St Louis encephalitis virus; Murray valley encephalitis virus; Duck tembusu virus; Turkey Meningoencephalitis Virus; Usutu virus; Sepik virus; Wesselsbron virus; Baiyangdian Virus; and Sitiawan Virus.

6. The chimeric flavivirus polyprotein of claim 1 comprising an amino acid sequence set forth in a sequence selected from the group consisting of SEQ ID NOS: 32, 389, 391, 395, and 393.

7. The chimeric flavivirus polyprotein of claim 1, which is encoded by a nucleotide sequence set forth in a sequence selected from the group consisting of SEQ ID NOS: 33, 386, 388, 390, 392, and 394.

8. An isolated nucleic acid encoding the chimeric flavivirus polyprotein of claim 1.

9. A genetic construct comprising the nucleic acid of claim 8.

10. An isolated host cell comprising the genetic construct of claim 9.

11. An isolated chimeric insect-specific flavivirus comprising the proteins of the chimeric flavivirus polyprotein of claim 1.

12. A vector comprising: (i) the nucleic acid of claim 8; and (ii) an insect-specific promoter operably connected to the nucleic acid of (i).

13. A method of producing an isolated chimeric insect-specific flavivirus, the method including the steps of: (a) combining a vector comprising (i) a nucleotide sequence capable of replicating the chimeric insect-specific flavivirus, the chimeric insect-specific flavivirus comprising: the proteins of the chimeric flavivirus polyprotein of claim 1; and a nucleic acid that encodes said chimeric flavivirus polyprotein of claim 1; and (ii) an insect-specific promoter operably connected to (i), with an insect cell; and (b) allowing said chimeric insect-specific flavivirus replicable by (i) to replicate in the insect cell, to thereby produce the isolated chimeric insect-specific flavivirus.

14. The method of claim 13, wherein one or more mutations are incorporated into the chimeric insect-specific flavivirus during replication in an insect cell.

15. A method of eliciting an immune response in a subject in need thereof comprising administering an effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises one or more group members selected from the group consisting of: (a) the chimeric flavivirus polyprotein of claim 1; (b) a genetic construct comprising a nucleic acid that encodes the chimeric flavivirus polyprotein of (a); (c) a vector comprising a nucleic acid that encodes the chimeric flavivirus polyprotein of (a) and an insect-specific promoter operably connected to the nucleic acid of (b); and (d) an isolated chimeric insect-specific flavivirus comprising the proteins of the chimeric flavivirus polyprotein of (a); and a nucleic acid that encodes said chimeric flavivirus polyprotein of (a).

16. A method of detecting, identifying or screening for an antibody in a sample, the method including the steps of combining a diagnostic composition with the sample, the diagnostic composition comprising one or both group members selected from the group consisting of: (a) the chimeric flavivirus polyprotein of claim 1 and (b) an isolated chimeric insect-specific flavivirus comprising the chimeric flavivirus polyprotein of (a); and a nucleic acid that encodes said chimeric flavivirus polyprotein of (a); wherein binding of an antibody in the sample to an immunogenic amino acid sequence of the chimeric flavivirus polyprotein or the isolated chimeric insect-specific flavivirus of the diagnostic composition facilitates detecting, identifying or screening for the antibody in the sample.

17. The chimeric flavivirus polyprotein of claim 1, wherein the immunogenic amino acid sequence (ii) is a prM protein and an Envelope protein.

18. The chimeric flavivirus polyprotein of claim 4, wherein the vertebrate-infecting flavivirus is selected from the group consisting of a mammalian-infecting flavivirus; a human-infecting flavivirus; an avian-infecting flavivirus; and a reptile-infecting flavivirus.

19. The chimeric flavivirus polyprotein of claim 1, further comprising a non-structural protein encoded by the genome of the flavivirus that is not insect specific.

20. The chimeric flavivirus polyprotein of claim 19, wherein the non-structural protein is NS1.

21. The chimeric flavivirus polyprotein of claim 1, which is capable of forming a virus particle.

22. The chimeric flavivirus polyprotein of claim 1, wherein the Lineage II insect-specific flavivirus of (i) is selected from the group consisting of Binjari virus (BinJV); Lilly Creek Virus (LiCV); Ilomantsi virus (ILOV); Donggang virus (DONV); Marisma mosquito virus (MMV); Chaoyang virus (CHAOV); and Lammi virus (LAMV).

23. The chimeric flavivirus polyprotein of claim 1, wherein the genome of the Lineage II insect-specific flavivirus is genetically modified.

24. The chimeric flavivirus polyprotein of claim 1, wherein the immunogenic amino acid sequence (ii) is an amino acid sequence set forth in SEQ ID NO: 8, 9 or 10.

25. The chimeric flavivirus polyprotein of claim 1, wherein the immunogenic sequence (ii) is the EDIII domain of the E protein encoded by the genome of the flavivirus that is not insect-specific.

26. The chimeric flavivirus polyprotein of claim 1, wherein the polyprotein backbone comprises the amino acid sequence of SEQ ID NO: 387 or 397.

27. The chimeric flavivirus polyprotein of claim 1, wherein the polyprotein backbone comprises the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 386 or 396.

Description

BRIEF DESCRIPTION OF THE FIGURES

(1) In order that the invention may be readily understood and put into practical effect, preferred embodiments will now be described by way of example with reference to the accompanying figures, wherein:

(2) FIG. 1 illustrates general flavivirus virion structure.

(3) FIG. 2 provides a schematic of flavivirus replication.

(4) FIG. 3 provides a schematic of the generation of vectors of the invention using Circular Polymerase Extension Cloning (CPEC) and generation of insect-specific flaviviruses therefrom.

(5) FIG. 4 illustrates the structure of a preferred insect-specific flavivirus of the invention, wherein the insect-specific flavivirus comprises amino acid sequence of a first insect-specific flavivirus (Capsid and NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 amino acid sequence from Palm Creek virus) and an immunogenic sequence of a second flavivirus (prM and Envelope amino acid sequence from West Nile virus, KUNV subtype). Native Palm Creek virus and West Nile virus are illustrated for reference (top).

(6) FIG. 5 illustrates OpIE2 promoter optimisation. (a) Schematic of the 3′ termini of the OpIE2 (SEQ ID NO:15) and OpIE2-CA (SEQ ID NO:16) promoters; (b) TCID.sub.50 of P.sub.0 supernatants from C6/36 cells transfected with WNV.sub.KUN CPEC containing either the OpIE2 or OpIE2-CA promoter (n=3 biological replicates for each construct). Supernatants harvested 5 days post-transfection indicate that the OpIE2-CA promoter yields approximately 100-fold higher titres than the OpIE2 promoter. Error bars represent standard deviation and asterisks indicate significance (P value>0.05; two-tailed t-test).

(7) FIG. 6 illustrates generation of PaRV using CPEC. (a) A schematic representation for the assembly of infectious DNA for PaRV by CPEC reaction; (b) Visualisation of PaRV replication in mosquito (C6/36) cell monolayers inoculated with either an MOI of 0.1 PaRV.sub.WT or undiluted P.sub.0 PaRV.sub.CPEC. Monolayers were fixed 72 hrs post-infection. IFA analysis was performed by probing with PaRV mouse anti-sera. The nucleus of each cell was stained with Hoechst 33342. Images were taken at ×40 magnification.

(8) FIG. 7 illustrates components of a nucleic acid comprising an insect-specific promoter (OpIE2) used for generation of a preferred vector of the invention by CPEC.

(9) FIG. 8 sets forth results of phenotypic analysis of PaRV.sub.WT and PaRV.sub.CPEC. (a) Comparative growth kinetics of PaRV.sub.WT, PaRV.sub.CPEC and WNV.sub.KUN in C6/36 cells. C6/36 cells were infected with either PaRV.sub.WT, PaRV.sub.CPEC or WNV.sub.KUN at an MOI of 0.1. Infectious titres at each time point were determined by titration of culture supernatant on to fresh C6/36 cells with infection detected using fixed cell ELISA. Error bars represent standard deviation and asterisks indicate significance (P value>0.001) as determined by a two-way ANOVA. (b) Comparison of reciprocal titres for the reactivity of a panel of anti-PaRV (5B7, 2G3, 2G10, 7D11, 3G7, 5D8, 2D2 and 1E5) and anti-PCV control (5G12) mAbs to PaRV.sub.WT and PaRV.sub.CPEC.

(10) FIG. 9 sets forth visualisation of WT and IFNAR.sup.−/− MEF cells infected with either WNV.sub.KUN or PaRV at an MOI of 0.1. Monolayers were fixed 72 hrs post-infection. IFA analysis was performed by probing with anti-PaRV (7D11), anti-WNV.sub.KUN (3.91D) and anti-dsRNA (3G1) mouse antibodies. The nucleus of each cell was stained with Hoechst 33342. Images were taken at ×40 magnification.

(11) FIG. 10 sets forth replication of chimeric flaviviruses. (a) Visualisation of C6/36 cells transfected with CPEC constructs of either WNV.sub.KUN, PaRV, WNV.sub.KUN/PaRV-prME or PaRV/WNV.sub.KUN-prME chimeras. IFA analysis was performed by probing with anti-PaRV (7D11), anti-WNV.sub.KUN E (3.91D) and anti-WNV.sub.KUN NS1 (3.1112G) mouse antibodies. (b) Visualisation of C6/36 cells transfected with a chimeric CPEC construct of WNV.sub.KUN/CFAV-prME. IFA analysis was performed by probing with anti-dsRNA (3G1), anti-WNV E (4G2) and anti-WNV NS1 (4G4) mouse antibodies. (c) Visualisation of C6/36 cells transfected with a chimeric CPEC construct of WNV.sub.KUN/PCV-prME. IFA analysis was performed by probing with anti-PCV E (5G12), anti-PCV NS1 (9G4/3D6), anti-WNV.sub.KUN E (3.91D) and anti-WNV.sub.KUN NS1 (3.1112G) mouse antibodies. Monolayers were fixed 5 days post-transfection. The nucleus of each cell was stained with Hoechst 33342. Images were taken at ×40 magnification.

(12) FIG. 11 sets forth host range of various flavivirus types.

(13) FIG. 12 sets forth SEQ ID NO:1 in FASTA format.

(14) FIG. 13 sets forth SEQ ID NO:2 in FASTA format.

(15) FIG. 14 sets forth SEQ ID NO:3 in FASTA format.

(16) FIG. 15 sets forth SEQ ID NO:4 in FASTA format.

(17) FIG. 16 sets forth SEQ ID NO:5 in FASTA format.

(18) FIG. 17 sets forth SEQ ID NO:6 in FASTA format.

(19) FIG. 18 sets forth SEQ ID NO:7 in FASTA format.

(20) FIG. 19 sets forth SEQ ID NO:8 in FASTA format.

(21) FIG. 20 sets forth SEQ ID NO:9 in FASTA format.

(22) FIG. 21 sets forth SEQ ID NO:10 in FASTA format.

(23) FIG. 22 sets forth SEQ ID NO:11 with nucleotide sequence numbering.

(24) FIG. 23 sets forth SEQ ID NO:12 with nucleotide sequence numbering.

(25) FIG. 24 sets forth SEQ ID NO:13 with nucleotide sequence numbering.

(26) FIG. 25 sets forth SEQ ID NO:14 with nucleotide sequence numbering.

(27) FIG. 26 sets forth SEQ ID NO:17 in FASTA format.

(28) FIG. 27 sets forth SEQ ID NO:18 in FASTA format.

(29) FIG. 28 sets forth SEQ ID NO:19 in FASTA format.

(30) FIG. 29 sets forth SEQ ID NO:20 in FASTA format.

(31) FIG. 30 sets forth SEQ ID NO:21 with nucleotide sequence numbering.

(32) FIG. 31 sets forth SEQ ID NO:22 in FASTA format.

(33) FIG. 32 sets forth SEQ ID NO:23 with nucleotide sequence numbering.

(34) FIG. 33 sets forth SEQ ID NO:24 in FASTA format.

(35) FIG. 34 sets forth SEQ ID NO:25 with nucleotide sequence numbering.

(36) FIG. 35 sets forth SEQ ID NO:26 in FASTA format.

(37) FIG. 36 sets forth SEQ ID NO:27 with nucleotide sequence numbering.

(38) FIG. 37 sets forth SEQ ID NO:28 in FASTA format.

(39) FIG. 38 sets forth SEQ ID NO:29 with nucleotide sequence numbering.

(40) FIG. 39 sets forth SEQ ID NO:30 in FASTA format.

(41) FIG. 40 sets forth SEQ ID NO:31 with nucleotide sequence numbering.

(42) FIG. 41 sets forth SEQ ID NO:32 in FASTA format.

(43) FIG. 42 sets forth SEQ ID NO:33 with nucleotide sequence numbering.

(44) FIG. 43 sets forth SEQ ID NO:34 with nucleotide sequence numbering.

(45) FIG. 44 sets forth SEQ ID NO:35 with nucleotide sequence numbering.

(46) FIG. 45 sets forth SEQ ID NO:36 with nucleotide sequence numbering.

(47) FIG. 46 sets forth SEQ ID NO:37 with nucleotide sequence numbering.

(48) FIG. 47 sets forth SEQ ID NO:38 with nucleotide sequence numbering.

(49) FIG. 48 sets forth SEQ ID NO:39 with nucleotide sequence numbering.

(50) FIG. 49 sets forth SEQ ID NO:40 with nucleotide sequence numbering.

(51) FIG. 50 sets forth SEQ ID NO:41 with nucleotide sequence numbering.

(52) FIG. 51 sets forth SEQ ID NO:42 with nucleotide sequence numbering.

(53) FIG. 52 sets forth SEQ ID NO:43 with nucleotide sequence numbering.

(54) FIG. 53 sets forth SEQ ID NO:44 with nucleotide sequence numbering.

(55) FIG. 54 sets forth SEQ ID NO:45 with nucleotide sequence numbering.

(56) FIG. 55 sets forth SEQ ID NO:46 with nucleotide sequence numbering.

(57) FIG. 56 sets forth SEQ ID NO:47 with nucleotide sequence numbering.

(58) FIG. 57 sets forth SEQ ID NOS:382-383 in FASTA format.

(59) FIG. 58 sets forth a time-course of infection of C6/36 cells by CPEC-derived PCV.

(60) FIG. 59 sets forth SEQ ID NO:384 in FASTA format.

(61) FIG. 60 sets forth SEQ ID NO:385 with nucleotide sequence numbering.

(62) FIG. 61 illustrates the structure of a chimeric E protein comprising an immunogenic EDIII domain. Flavivirus E protein has 3 domains: DI, DII and DIII (A). ISF-VIF EDIII chimeras will produce virions comprising ISF structural proteins, except for VIF EDIII (blue, B).

(63) FIG. 62 sets forth SEQ ID NO:386 in FASTA format.

(64) FIG. 63 sets forth SEQ ID NO:387 in FASTA format.

(65) FIG. 64 sets forth SEQ ID NO:388 in FASTA format.

(66) FIG. 65 sets forth SEQ ID NO:389 in FASTA format.

(67) FIG. 66 sets forth SEQ ID NO:390 in FASTA format.

(68) FIG. 67 sets forth SEQ ID NO:391 in FASTA format.

(69) FIG. 68 sets forth SEQ ID NO:392 in FASTA format.

(70) FIG. 69 sets forth SEQ ID NO:393 in FASTA format.

(71) FIG. 70 sets forth SEQ ID NO:394 in FASTA format.

(72) FIG. 71 sets forth SEQ ID NO:395 in FASTA format.

(73) FIG. 72 sets forth SEQ ID NO:396 in FASTA format.

(74) FIG. 73 sets forth SEQ ID NO:397 in FASTA format.

(75) FIG. 74 sets forth nucleotide (non-bold) and amino acid (bold) sequence similarity (percentage) between lineage II ISFs (dISFs) over ORF sequences. For BinJV and LiCV (labelled LLCFC), ORF sequences were as described herein. For the remaining lineage II ISFs, ORF sequence were obtained from the following Genbank references: EU159426 (NOUV), KC692068 (LAMV), JQ308185 (CHAOV), KC692067 (ILOV), KX359172 (PANFV), NC_016997 (DONV), JN603190 (MMV), JX627335 (NANV), KJ210048 (NHUV), KC496020 (BJV).

(76) FIG. 75 sets forth nucleotide and amino acid sequence similarity (percentage) of lineage I ISFs (cISFs) over ORF sequences. Top-right half of the table is amino acid sequence similarity and bottom left half is nucleotide sequence similarity. PaRV: Parramatta River virus; CFAV: Cell fusing agent virus; CxFV: Culex flavivirus; QBV: Quang Binh virus; PCV: Palm Creek virus.

(77) FIG. 76 sets forth a maximum likelihood analysis over ORF amino acid sequences for phylogenetic assessment of Lilly Creek virus (labelled LiLV) compared to BinJV as described herein and the sequences obtained from the following Genbank references (with virus name in brackets): AB488408 (AEFV); AY898809 (ALFV); KF917535 (AROAV); KM225264 (Bainyik virus); DQ859056 (BANV); KU308380 (BgV); (LLCFV); KC496020 (BJV); KJ741267 (CFAV); JQ308185 (CHAOV); HE574574 (CTFV); U88536 (DENY-1); U87411 (DENY-2); AY099336 (DENY-3); AF326825 (DENY-4); DQ859060 (EHV); DQ837641 (ENTV); DQ235145 (GGYV); NC_030401 (HANKY); KC692067 (ILOV); M18370 (JEV); DQ859066 (JUGV); AY632541 (KOKV); AY149905 (KRV); KC692068 (LAMV); KC692067 (LIV); AJ242984 (MODV); AF161266 (MVEV); NC_030400 (NAKV); KJ210048 (NHUV); JQ957875 (NIEV); KC788512 (NMV); EU159426 (NOUV); AY193805 (OHFV); KT192549 (PaRV); KC505248 (PCV); DQ859067 (POTV); L06436 (POWV); FJ644291 (QBV); NC_003675 (RBV); DQ859062 (SABV); DQ837642 (SEPV); DQ525916 (SLEV); DQ859064 (SPOV); DQ235150 (SREV); KM225263 (STRV); U27495 (TBEV); KM225265 (Torres virus); DQ859065 (UGSV); JN226796 (WESSV); KY229074 (WNV); X03700 (YFV); AB114858 (YOKV); AY632535 (ZIKV).

(78) FIG. 77 sets forth analysis of LiCV growth in mosquito (C6/36, mos55) and vertebrate (BSR, Vero) cell lines. West Nile virus (WNV.sub.KUN) is also included as a control.

(79) FIG. 78 sets forth amino acid similarity of BinJV and LiCV envelope proteins in comparison to vertebrate-infecting flavivirus envelope proteins.

(80) FIG. 79 sets forth a comparison of the growth of BinJV and associated chimeras to that of PCV and an associated chimera.

(81) FIG. 80 sets forth an assessment of BinJV host restriction. (A) Immunofluorescence images of BinJV, WNV.sub.KUN, and Mock inoculated insect cells lines (S2, mos55, HSU, Chao Ball, RML-12, and C636). (B) Immunofluorescence images of BinJV (bottom), WNV.sub.KUN (middle), and Mock (top) inoculated vertebrate cell lines (BSR, DF-1, Vero, OK, SW-13, MEF wild type, and MEF IFNAR.sup.4-). A tabulated summary of replication results in (A) and (B) is provided at the top of the figure.

(82) FIG. 81 sets forth an assessment of host restriction of the BinJV-WNV.sub.KUN-prME chimeric ISF vector at standard temperature (37° C.) and lowered temperature (34° C.). (A) Immunofluorescence images of BinJV, WNV.sub.KUN, BinJV/WNV.sub.KUN-prME, and Mock inoculated cell lines C6/36 (mosquito); and BSR, Vero, MEF.sub.WT and MEF.sub.IFNAR.sup.−/− (vertebrate) at 37° C. (B) Immunofluorescence images of BinJV, WNV.sub.KUN, BinJV/WNV.sub.KUN-prME, and Mock inoculated cell lines C6/36 (mosquito); and BSR, Vero, MEF.sub.WT and MEF.sub.IFNAR.sup.−/− (vertebrate) at 34° C.

(83) FIG. 82 sets forth an assessment of replication of BinJV/DENV1-prME (labelled BinJV-DENV.sub.prME) and BinJV/ZIKV-prME (labelled BinJV-ZIKVprME) in mosquito cells. Top: results of staining (green) of mosquito cells inoculated with chimeric ISFs using an anti-DENY or anti-ZIKV E protein antibody (top); and an anti-BinJV E protein (bottom).

(84) FIG. 83 sets forth an assessment of mutation of EDII fusion loop in BinJV and LiCV. (A) An alignment of E domain II residues (blue box) in BinJV, LiCV and other flaviviruses. Conserved residues are highlighted. Fusion loop is indicated by red box. BinJV (SEQ ID NO: 406) and LiCV (SEQ ID NO: 407) sequences used were as described herein. Sequence for the other flaviviruses was obtained from the following Genbank references: KC692068 (LAMV) (SEQ ID NO: 412); JQ308185 (CHAOV) (SEQ ID NO: 411); KC692067 (ILOV) (SEQ ID NO: 410); EU159426 (NOUV) (SEQ ID NO: 408); KJ210048 (NHUV) (SEQ ID NO: 409); KC496020 (BJV) (SEQ ID NO: 413); U88536 (DENV-1) (SEQ ID NO: 416); AY632535 (ZIKV) (SEQ ID NO: 417); M18370 (JEV) (SEQ ID NO: 414); KY229074 (WNV) (SEQ ID NO: 415). (B) Immunofluorescence analysis of 4G2 detection of wild-type BinJV (BinJV.sub.WT V106) and BinJV with key mutated residue (BinJV.sub.V106G).

(85) FIG. 84 sets forth immunofluorescent confirmation of the successful production of a BinJV/WNVEDI (labelled BinJV-WNV.sub.EDI) chimera wherein a 19 amino acid peptide from the WNV E protein was inserted into the homologous region of DI of BinJV. For comparison BinJV/WNV.sub.KUN-prME (labelled BinJV-WNV.sub.STR) is included. Interpretation of the staining is indicated in the bottom right-hand corner of each image.

(86) FIG. 85 sets forth (A) immunofluorescent confirmation of production of PCV/Vertebrate-Infecting Flavivirus(VIF)-prME chimeras PCV/DENV-prME (labelled PCV-DENV.sub.STR), PCV/ZIKV-prME (labelled PCV-ZIKV.sub.STR), and PCV/WNV.sub.KUN-prME (labelled PCV-WNV.sub.STR) in C6/36 mosquito cells; and (B) exemplary assessment of replication of PCV/VIF-prME chimeras in comparison with replication of PCV and the applicable VIF in C6/36 mosquito cells; specifically, replication of PCV, DENV, and PCV/DENV-prME (labelled PCV-DENV.sub.STR); and replication of PCV, ZIKV, and PCV/ZIKV-prME (labelled PCV-ZIKV.sub.STR) (bottom) is shown.

(87) FIG. 86 sets forth growth kinetics of chimeric ISF vectors before and after serial passaging in C6/36 mosquito cells. (A) Replication in C6/36 cells of: PCV/WNV.sub.KUN-prME not exposed to serial passaging (P1); PCV/WNV.sub.KUN-prME serially passaged 10 times (P10); and wild type PCV. (B) Replication in mosquito cells of PCV/ZIKV-prME not exposed to serial passaging (P1); PCV/ZIKV-prME serially passaged 10 times (P10); and wild type PCV.

(88) FIG. 87 sets forth an assessment of the use of PCV/WNV.sub.KUN-prME in ELISA to detect WNV-specific antibodies in human, horse, and crocodile sera.

(89) FIG. 88 sets forth binding of PCV/ZIKV-prME particles by ZIKV positive and ZIKV naïve human serum.

(90) FIG. 89 sets forth neutralisation of PCV/WNV.sub.KUN-prME (labelled PCV-WNV.sub.STR), BinJV/WNV.sub.KUN-prME (labelled BinJV-WNV.sub.STR), and wild type WNV replication using dilutions of virus positive and naïve (A) human; (B) horse; (C) crocodile; and (D) rabbit sera.

(91) FIG. 90 sets forth neutralisation of PCV/ZIKV-prME (labelled PCV-ZIKV.sub.STR) and wild type ZIKV replication by dilutions of ZIKV-positive human sera and ZIKV monoclonal antibodies.

(92) FIG. 91 sets forth IFA staining of C6/36 mosquito cells infected with PaRV/KRBV-prM and wild type PaRV. Positive staining of anti-PaRV E mAb occurs to chimeric and wild type infected cells. In contrast, a mAb specific to PaRV-prM only detected wild type-PaRV and not the PaRV/KRBV-prM chimera.

(93) FIG. 92 sets forth confirmation at P0 and P1 by RT-PCR of RNA extracted from PCV/KRBV-prME-infected cells. The RT-PCR was performed with KRBV E protein-specific primers (band at 800 bp). Extracted RNA from PCV and KRBV served as negative and positive controls, respectively, while a no template control (NTC) served as an additional negative control.

(94) FIG. 93 sets forth an assessment of cross reactivity of BinJV and KUNV.

(95) FIG. 94 sets forth SEQ ID NO:398 in FASTA format.

(96) FIG. 95 sets forth SEQ ID NO:399 in FASTA format.

(97) FIG. 96 sets forth SEQ ID NO:400 with nucleotide sequence numbering.

(98) FIG. 97 sets forth SEQ ID NO:401 with nucleotide sequence numbering.

(99) FIG. 98 sets forth SEQ ID NO:402 with amino acid sequence numbering.

(100) FIG. 99 sets forth SEQ ID NO:403 with amino acid sequence numbering.

(101) FIG. 100 sets forth SEQ ID NO:404 with amino acid sequence numbering.

(102) FIG. 101 sets forth SEQ ID NO:405 with amino acid sequence numbering.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

(103) SEQ ID NO:1 Amino acid sequence of a PCV/WNV.sub.KUN-prME chimeric ISF protein comprising C and NS1-NS5 proteins from PCV and prM and E proteins from West Nile virus Kunjin subtype (WNV.sub.KUNV).

(104) SEQ ID NO:2 Amino acid sequence of a PCV/ZIKA-prME chimeric ISF protein comprising C and NS1-NS5 proteins from PCV and prM and E proteins from ZIKA.

(105) SEQ ID NO:3 Amino acid sequence of a PCV/DENV2-prME chimeric ISF protein comprising C and NS1-NS5 proteins from PCV and prM and E proteins from DENV2.

(106) SEQ ID NO:4 Amino acid sequence of a BgV/WNV.sub.KUN-prME chimeric ISF protein comprising C and NS1-NS5 proteins from BgV and prM and E proteins from WNV.sub.KUNV.

(107) SEQ ID NO:5 Amino acid sequence of a PCV polyprotein.

(108) SEQ ID NO:6 Amino acid sequence of a BinJV polyprotein.

(109) SEQ ID NO:7 Amino acid sequence of a BgV polyprotein.

(110) SEQ ID NO:8 Amino acid sequence of a WNV.sub.KUN polyprotein.

(111) SEQ ID NO:9 Amino acid sequence of a ZIKA polyprotein.

(112) SEQ ID NO:10 Amino acid sequence of a DENV2 polyprotein.

(113) SEQ ID NO:11 Nucleotide sequence of a PCV/WNV.sub.KUN-prME chimeric ISF vector.

(114) SEQ ID NO:12 Nucleotide sequence of a PCV/ZIKA-prME chimeric ISF vector.

(115) SEQ ID NO:13 Nucleotide sequence of a PCV/DENV2-prME chimeric ISF vector.

(116) SEQ ID NO:14 Nucleotide sequence of a BgV/WNV.sub.KUNV-prME chimeric ISF vector.

(117) SEQ ID NO:15 Nucleotide sequence of an OpIE2 promoter.

(118) SEQ ID NO:16 Nucleotide sequence of an OpIE2-CA promoter.

(119) SEQ ID NO:17 Amino acid sequence of a KRBV polyprotein.

(120) SEQ ID NO:18 Amino acid sequence of a Parramatta River virus polyprotein.

(121) SEQ ID NO:19 Amino acid sequence of a CFAV polyprotein.

(122) SEQ ID NO:20 Amino acid sequence of a WNV.sub.KUN/PCV-prME chimeric ISF protein comprising C and NS1-NS5 proteins from WNV.sub.KUN and prM and E proteins from PCV.

(123) SEQ ID NO:21 Nucleotide sequence of a WNV.sub.KUN/PCV-prME chimeric ISF vector.

(124) SEQ ID NO:22 Amino acid sequence of a WNV.sub.KUN/BgV-prME chimeric ISF protein comprising C and NS1-NS5 proteins from WNV.sub.KUN and prM and E proteins from BgV.

(125) SEQ ID NO:23 Nucleotide sequence of a WNV.sub.KUN/BgV-prME chimeric ISF vector.

(126) SEQ ID NO:24 Amino acid sequence of a WNV.sub.KUN/BinJV-prME chimeric ISF protein comprising C and NS1-NS5 proteins from WNV.sub.KUN and prM and E proteins from BinJV.

(127) SEQ ID NO:25 Nucleotide sequence of a WNV.sub.KUN/BinJV-prME chimeric ISF vector.

(128) SEQ ID NO:26 Amino acid sequence of WNV.sub.KUN/CFAV-prME chimeric ISF protein comprising C and NS1-NS5 proteins from WNV.sub.KUN and prM and E proteins from BinJV.

(129) SEQ ID NO:27 Nucleotide sequence of WNV.sub.KUN/CFAV-prME chimeric ISF vector.

(130) SEQ ID NO:28 Amino acid sequence of WNV.sub.KUN/KRBV-prME chimeric ISF protein comprising C and NS1-NS5 proteins from WNV.sub.KUN and prM and E proteins from KRBV.

(131) SEQ ID NO:29 Nucleotide sequence of WNV.sub.KUN/KRBV-prME chimeric ISF vector.

(132) SEQ ID NO:30 Amino acid sequence of WNV.sub.KUN/PaRV-prME chimeric ISF protein comprising C and NS1-NS5 proteins from WNV.sub.KUN and prM and E proteins from PaRV.

(133) SEQ ID NO:31 Nucleotide sequence of WNV.sub.KUN/PaRV-prME chimeric ISF vector.

(134) SEQ ID NO:32 Amino acid sequence of BinJV/WNV.sub.KUNV-EDIII chimeric ISF protein.

(135) SEQ ID NO:33 Nucleotide sequence of BinJV/WNV.sub.KUNV-EDIII chimeric ISF protein.

(136) SEQ ID NO:34 Nucleotide sequence of CPEC vector encoding BgV polyprotein driven by OpIE2-CA.

(137) SEQ ID NO:35 Nucleotide sequence of CPEC vector encoding BinJV polyprotein driven by OpIE2-CA.

(138) SEQ ID NO:36 Nucleotide sequence of CPEC vector encoding PCV polyprotein driven by OpIE2-CA.

(139) SEQ ID NO:37 Nucleotide sequence of CPEC vector encoding PaRV polyprotein driven by OpIE2-CA.

(140) SEQ ID NO:38 Nucleotide sequence of CPEC vector encoding WNV.sub.KUNV polyprotein driven by OpIE2-CA.

(141) SEQ ID NO:39 PCV genomic nucleotide sequence.

(142) SEQ ID NO:40 BinJV genomic nucleotide sequence.

(143) SEQ ID NO:41 BgV genomic nucleotide sequence.

(144) SEQ ID NO:42 KRBV genomic nucleotide sequence.

(145) SEQ ID NO:43 PaRV genomic nucleotide sequence.

(146) SEQ ID NO:44 CFAV genomic nucleotide sequence.

(147) SEQ ID NO:45 WNV.sub.KUN genomic nucleotide sequence

(148) SEQ ID NO:46 ZIKA genomic nucleotide sequence.

(149) SEQ ID NO:47 DENV2 genomic nucleotide sequence.

(150) SEQ ID NOS:48-79 CPEC primers for producing BgV/WNV.sub.KUN-prME vector.

(151) SEQ ID NOS:80-96 CPEC primers for producing BinJV/WNV.sub.KUN-EDIII vector.

(152) SEQ ID NOS:97-138 CPEC primers for producing WNV.sub.KUN/BgV-prME vector.

(153) SEQ ID NOS:139-173 CPEC primers for producing WNV.sub.KUN/BinJV-prME vector.

(154) SEQ ID NOS:174-208 CPEC primers for producing WNV.sub.KUN/CFAV-prME vector.

(155) SEQ ID NOS:209-241 CPEC primers for producing WNV.sub.KUN/KRBV-prME vector.

(156) SEQ ID NOS:242-282 CPEC primers for producing WNV.sub.KUN/PaRV-prME vector.

(157) SEQ ID NOS:283-317 CPEC primers for producing WNV.sub.KUN/PCV-prME vector.

(158) SEQ ID NOS:318-338 CPEC primers for producing PCV/DENV2-prME vector.

(159) SEQ ID NOS:339-360 CPEC primers for producing PCV/WNV.sub.KUN-prME vector.

(160) SEQ ID NOS:361-381 CPEC primers for producing PCV/ZIKV-prME vector.

(161) SEQ ID NO:382 P10 promoter sequence of AcMNP.

(162) SEQ ID NO:383 Polyhedrin promoter sequence of AcMNP.

(163) SEQ ID NO:384 Amino acid sequence of PaRV/WNV.sub.KUN-prME chimeric ISF protein comprising C and NS1-NS5 proteins from PaRV and prM and E proteins from WNV.sub.KUN.

(164) SEQ ID NO:385 Nucleotide sequence of PaRV/WNV.sub.KUN-prME chimeric ISF vector.

(165) SEQ ID NO:386 Genomic nucleotide sequence of Lilly Creek virus (LiCV).

(166) SEQ ID NO:387 Amino acid sequence of ORF of Lilly Creek virus.

(167) SEQ ID NO:388 Nucleotide sequence of BinJV-WNV.sub.KUNV-prME chimeric ISF vector.

(168) SEQ ID NO:389 Amino acid sequence of BinJV/WNV.sub.KUNV-prME ORF.

(169) SEQ ID NO:390 Nucleotide sequence of BinJV/ZIKV-prME chimeric ISF vector.

(170) SEQ ID NO:391 Amino acid sequence of BinJV/ZIKV-prME ORF.

(171) SEQ ID NO:392 Nucleotide sequence of BinJV/WNVED1 chimeric ISF vector.

(172) SEQ ID NO:393 Amino acid sequence of BinJV/WNVED1 ORF.

(173) SEQ ID NO:394 Nucleotide sequence of BinJV/DENV1-prME chimeric ISF vector.

(174) SEQ ID NO:395 Amino acid sequence of BinJV/DENV1-prME ORF.

(175) SEQ ID NO:396 Nucleotide sequence of BinJV.sub.V106G vector.

(176) SEQ ID NO:397 Amino acid sequence of BinJV.sub.V106G ORF.

(177) SEQ ID NO:398 Nucleotide sequence of PaRV/KRBV-prM chimeric ISF vector.

(178) SEQ ID NO:399 Nucleotide sequence of PCV/KRBV-prME chimeric ISF vector.

(179) SEQ ID NO:400 Nucleotide sequence of PCV/ZIKV-prME P1 chimeric ISF vector.

(180) SEQ ID NO:401 Nucleotide sequence of PCV/ZIKV-prME P10 chimeric ISF vector.

(181) SEQ ID NO:402 Amino acid sequence of PaRV/KRBV-prM ORF.

(182) SEQ ID NO:403 Amino acid sequence of PCV/ZIKV-prME P1 ORF.

(183) SEQ ID NO:404 Amino acid sequence of PCV/ZIKV-prME P10 ORF.

(184) SEQ ID NO:405 Amino acid sequence of PaRV/KRBV-prME ORF.

DETAILED DESCRIPTION

(185) The present invention is partly predicated on the realization that chimeric insect-specific flaviviruses, and proteins and/or particles thereof, offer potential for new vaccines. The invention is also partly predicated on the realization that chimeric insect-specific flaviviruses, and proteins and/or particles thereof, offer potential for new diagnostics.

(186) In particular, the inventors have realised that chimeric insect-specific flaviviruses (and corresponding proteins and/or particles) containing immunogenic sequence can potentially be used directly for vaccination of vertebrate subjects (e.g. humans; avians; reptiles), as these insect-specific flaviviruses are not expected to substantially replicate in or infect non-insect cells. The inventors have further realised that chimeric insect-specific flaviviruses (and corresponding proteins and/or particles) may be useful in assays for the detection of antibodies, and may have advantages (for example in relation to safety; efficacy; and/or specificity) in this context.

(187) The invention is also partly predicated on the discovery of design elements important for the construction of vectors to allow for the production of chimeric insect-specific flaviviruses, and proteins and/or particles thereof, from insect cells.

(188) Isolated Proteins

(189) Accordingly, one aspect of the invention provides an isolated protein comprising:

(190) (i) an amino acid sequence of a protein encoded by the genome of an insect-specific flavivirus; and

(191) (ii) an immunogenic amino acid sequence not encoded by the genome of an insect-specific flavivirus.

(192) For the purposes of this invention, by “isolated” is meant material (e.g. proteins, nucleic acids, cells etc.) that has been removed from its natural state or otherwise been subjected to human manipulation. Isolated material may be substantially or essentially free from components that normally accompany it in its natural state, or may be manipulated so as to be in an artificial state together with components that normally accompany it in its natural state. Isolated material may be in native, chemical synthetic or recombinant form.

(193) As used herein, “flavirus”, “flaviruses”, “flaviviral” etc. refers to members of the genus Flavivirus within the family Flaviviridae. As will be readily understood by the skilled person flaviviruses are enveloped viruses, with icosahedral or spherical geometries, and a typical diameter of around 50 nm. Flaviviruses comprise structural and non-structural proteins. Specifically, flavivirus proteins typically comprise three structural proteins (Capsid, prM, and Envelope) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5).

(194) It will be understood that the term protein “protein” is used herein to mean an amino acid polymer, comprising natural and/or non-natural amino acids, including L- and D-isomeric forms as are well understood in the art. Additionally, for the purposes of this invention, it will be understood that the term “protein” includes and encompasses both individual protein subunits, and complexes of individual protein subunits. As will be readily appreciated by the skilled person, flavivirus proteins typically originate as a single ‘polyprotein’, which is subsequently processed into the individual structural and non-structural proteins of the flavivirus during replication. It will be understood that an isolated protein of this aspect includes such polyproteins, as well as complexes of any or all individual structural and/or non-structural flavivirus protein subunits, as described above.

(195) It will be further appreciated that, in addition to structural and non-structural proteins, flaviviruses comprise a nucleic acid genome encoding these proteins. Specifically, flavivirus genomes are linear positive-sense RNA and non-segmented, and generally about 10-11 kb in length. The genomic RNA is typically modified at the 5′ end with a cap-1 structure.

(196) In the context of this invention, an “insect-specific flavivirus” (or “ISF”) will be understood to be a flavivirus which infects a suitable insect host and/or grows and replicates in suitable insect cell lines, but which does not grow or replicate, or at least demonstrates substantially restricted growth or replication, in at least wild type vertebrate cell lines. For an overview of ISFs, the skilled person is directed to Calzolari et al. (2016) Infections, Genetics and Evolution, 40: 381-388, and Blitvich and Firth (2015) Viruses, 7: 1927-1959; incorporated herein by reference.

(197) For the purposes of this invention, ISFs will be understood to include known wild type ISFs, such as those described in Calzolari et al.; and Blitvich and Firth, supra, as well as flavivirus mutants, variants, recombinants, and derivatives etc. which similarly infect a suitable insect host and/or grow and replicate in suitable insect cell lines, but which do not grow or replicate, or at least demonstrate substantially restricted growth or replication, in at least wild type vertebrate cell lines. With reference to Colmant et al. (2016) Journal of General Virology, 97: 1087-1093, it will be appreciated that Bamaga virus (BgV) infects a mosquito host, and also demonstrates some restricted replication in certain wild type vertebrate cell lines. For the purposes of this invention, BgV, and similar viruses which infect an insect or mosquito host but also demonstrate some restricted replication in wild type vertebrate cell lines, will be considered an “ISF-like” virus.

(198) Typically, for the purpose of this invention, an ISF-like virus will be considered to fall within the scope of an insect-specific flavivirus. However, in certain embodiments, the insect-specific flavivirus excludes ISF-like viruses, such as BgV.

(199) The terms “immunogenic amino acid sequence”, “immunogenic sequence”, “immunogenic protein, etc. are used interchangeably herein with immunogen, antigen, epitope, antigenic sequence, polytope, immunogenic peptide, peptide, antigenic epitope etc. as is known in the art to denote or refer to a sequence capable of eliciting an immune response, and more particularly a specific or desired immune response such as protective immune response or memory immune response. The term immunogen broadly includes any type of molecule which is recognized by a host immune system as being foreign Immunogenic sequences of the invention may comprise B and/or T-cell epitopes.

(200) In certain particularly preferred embodiments, the isolated protein of this aspect is or comprises an amino acid sequence set forth in SEQ ID NOS:1-4 or SEQ ID NOS:32, 389, 391, or 395, or a fragment, variant, or derivative thereof. In certain embodiments, the isolated protein of this aspect is or comprises an amino acid sequence set forth in SEQ ID NOS:20, 22, 24, 26, 28, 30, 384, 393, 397, or 402-405, or a fragment or variant thereof.

(201) In certain embodiments, a “fragment” protein of this aspect comprises an amino acid sequence which constitutes less than 100%, but at least 20%, preferably at least 30%, more preferably at least 80% or even more preferably at least 90%, 95%, 96%, 97%, 98% or 99% of an amino acid sequence set forth in SEQ ID NOS:1-4 or SEQ ID NOS:32, 389, 391, or 395; or SEQ ID NOS:20, 22, 24, 26, 28, 30, 384, 393, 397, or 402-405. In one preferred embodiment the protein fragment comprises no more than 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, or 3400 contiguous amino acid sequences of an amino acid sequence set forth in SEQ ID NOS:1-4 or SEQ ID NOS:32, 389, 391, or 395; or SEQ ID NOS:20, 22, 24, 26, 28, 30, 384, or 397.

(202) As used herein a “variant” protein or nucleic acid, respectively, will be understood to be one in which one or more amino acids or nucleotides, respectively have been deleted or substituted by different amino acids or nucleotides, respectively. Variants include naturally occurring (e.g., allelic) variants, orthologs (e.g. from other species) and synthetic variants, such as produced in vitro using mutagenesis techniques.

(203) In some embodiments of this aspect, the isolated protein fragment includes an amino acid sequences having at least 75%, 80%, 85%, 90% or 95%, 96%, 97%, 98% or 99% amino acid sequence identity with a nucleotide sequence set forth in SEQ ID NOS:1-4, 32, 389, 391, or 395; or SEQ ID NOS:20, 22, 24, 26, 28, 30, 384, or 397.

(204) Terms used generally herein to describe sequence relationships between respective amino acid and nucleotide sequences and sequences include “comparison window”, “sequence identity”, “percentage of sequence identity” and “substantial identity”. Because respective nucleic acids/proteins may each comprise (1) only one or more portions of a complete nucleic acid/protein sequence that are shared by the nucleic acids/proteins, and (2) one or more portions which are divergent between the nucleic acids/proteins, sequence comparisons are typically performed by comparing sequences over a “comparison window” to identify and compare local regions of sequence similarity. A “comparison window” refers to a conceptual segment of typically 6, 9 or 12 contiguous residues that is compared to a reference sequence.

(205) The comparison window may comprise additions or deletions (i.e., gaps) of about 20% or less as compared to the reference sequence for optimal alignment of the respective sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerised implementations of algorithms (Geneworks program by Intelligenetics; GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, Wis., USA, incorporated herein by reference) or by inspection and the best alignment (i.e., resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as for example disclosed by Altschul et al., 1997, Nucl. Acids Res. 25 3389, which is incorporated herein by reference. A detailed discussion of sequence analysis can be found in Unit 19.3 of CURRENT PROTOCOLS IN MOLECULAR BIOLOGY Eds. Ausubel et al. (John Wiley & Sons Inc NY, 1995-1999).

(206) The term “sequence identity” is used herein in its broadest sense to include the number of exact nucleotide or amino acid matches having regard to an appropriate alignment using a standard algorithm, having regard to the extent that sequences are identical over a window of comparison. Thus, a “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U) or amino acid occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For example, “sequence identity” may be understood to mean the “match percentage” calculated by the DNASIS computer program (Version 2.5 for Windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, Calif., USA).

(207) A detailed discussion of sequence analysis can be found in Chapter 19.3 of Ausubel et al., supra.

(208) It will be appreciated that, without limitation, protein and nucleic acid variants can be created by mutagenizing a protein or an encoding nucleic acid, such as by random mutagenesis or site-directed mutagenesis. Examples of nucleic acid mutagenesis methods are provided in Chapter 9 of CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel et al., supra which is incorporated herein by reference. Mutagenesis may also be induced by chemical means, such as ethyl methane sulphonate (EMS) and/or irradiation means, such as fast neutron irradiation of seeds as known in the art (Carroll et al., 1985, Proc. Natl. Acad. Sci. USA 82 4162; Carroll et al, 1985, Plant Physiol. 78 34; Men et al., 2002, Genome Letters 3 147).

(209) Also included according to this aspect are derivative amino acid sequences and/or proteins.

(210) As used herein, “derivative” proteins are proteins that have been altered, for example by conjugation or complexing with other chemical moieties or by post-translational modification techniques as would be understood in the art. Such derivatives include amino acid deletions and/or additions to polypeptides of the invention, or variants thereof.

(211) “Additions” of amino acids may include fusion of the peptide or polypeptides of the invention, or variants thereof, with other peptides or polypeptides. Particular examples of such peptides include amino (N) and carboxyl (C) terminal amino acids added for use as fusion partners or tags.

(212) Well-known examples of fusion partners include hexahistidine (6X-HIS)-tag, N-Flag, Fc portion of human IgG, glutathione-S-transferase (GST) and maltose binding protein (MBP), which are particularly useful for isolation of the fusion polypeptide by affinity chromatography. For the purposes of fusion polypeptide purification by affinity chromatography, relevant matrices for affinity chromatography may include nickel-conjugated or cobalt-conjugated resins, fusion polypeptide specific antibodies, glutathione-conjugated resins, and amylose-conjugated resins respectively. Some matrices are available in “kit” form, such as the ProBond™ Purification System (Invitrogene Corp.) which incorporates a 6X-His fusion vector and purification using ProBond™ resin.

(213) The fusion partners may also have protease cleavage sites, for example enterokinase (available from Invitrogen Corp. as EnterokinaseMax™), Factor X.sub.a or Thrombin, which allow the relevant protease to digest the fusion polypeptide of the invention and thereby liberate the recombinant polypeptide of the invention therefrom. The liberated polypeptide can then be isolated from the fusion partner by subsequent chromatographic separation.

(214) Fusion partners may also include within their scope “epitope tags”, which are usually short peptide sequences for which a specific antibody is available.

(215) Other derivatives contemplated by the invention include, chemical modification to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide or polypeptide synthesis and the use of cross linkers and other methods which impose conformational constraints on the polypeptides, fragments and variants of the invention.

(216) Non-limiting examples of side chain modifications contemplated by the present invention include chemical modifications of amino groups, carboxyl groups, guanidine groups of arginine residues, sulphydryl groups, tryptophan residues, tyrosine residues and/or the imidazole ring of histidine residues, as are well understood in the art.

(217) Non-limiting examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, use of 4-amino butyric acid, 6-aminohexanoic acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 4-amino-3-hydroxy-6-methylheptanoic acid, t-butylglycine, norleucine, norvaline, phenylglycine, ornithine, sarcosine, 2-thienyl alanine and/or D-isomers of amino acids.

(218) In some preferred embodiments, the isolated protein of this aspect will be of an isolated chimeric insect-specific flavivirus, as hereinbelow described.

(219) Suitably, the isolated protein is, or is of, a virus particle. As used herein, a “virus particle” will be understood to encompass infectious complete virus particles, and subviral particles, as are well known in the art. In particular regard to subviral particles, as will be readily understood by the skilled person, these particles contain viral proteins but typically do not contain viral genetic material. As such, subviral particles are typically incapable of self-replication. Subviral particles will generally contain structural flavivirus proteins and may contain non-structural flavivirus proteins. One particular, non-limiting example of a subviral particle is a VLP.

(220) As is known in the art, subviral particles (inclusive of VLPs) may be produced by expression, e.g. in vitro expression, of viral proteins followed by assembly of these proteins. For an overview of subviral particle (e.g. VLP) production, the skilled person is directed to Machida and Imataka (2015) Biotechnology Letters 37(4): 753-760, incorporated herein by reference. Isolated subviral particles may also potentially be produced by purification of a corresponding isolated chimeric insect-specific flavivirus, such as hereinbelow described, to remove genetic material from the flavivirus.

(221) Amino Acid Sequence of Proteins Encoded by the Genome of an Insect-Specific Flavivirus

(222) As set forth above, the amino acid sequence (i) of the isolated protein of this aspect will be of, or derived from, a protein encoded by the genome of an insect-specific flavivirus (ISF).

(223) With reference to Colmant et al. (2017) mSphere 2(4) pii: e00262-17, it will be appreciated that insect-specific flaviviruses may be classified as ‘Lineage I’ or ‘Lineage II’ ISFs. In certain embodiments, the amino acid sequence (i) is of, or derived from, a protein encoded by the genome of a Lineage I ISF. In certain embodiments, the amino acid sequence (i) is of, or derived from, a protein encoded by the genome of a Lineage II ISF.

(224) Preferably, the insect-specific flavivirus encoding said amino acid sequence is capable of infecting a plurality of different insect cells. In preferred embodiments, said insect-specific flavivirus is capable of infecting a plurality of species of insect cells. In particularly preferred embodiments, said first insect-specific flavivirus is capable of infecting a plurality of genera of insect cells.

(225) With reference to the examples and FIG. 11, it will be appreciated that the use of an insect-specific flavivirus capable of infecting a plurality of genera of insect cells has been observed to be particularly effective for the production of chimeric insect-specific flaviviruses of the invention, which comprise isolated proteins according to certain preferred embodiments of this aspect. Without being bound by theory, the inventors hypothesize that the use of an amino acid sequence (i) of or derived from a protein encoded by the genome of an insect-specific flavivirus wherein the flavivirus can infect a plurality of genera and/or species of insect cells may be generally desirable for producing isolated insect-specific flaviviruses. Therefore, proteins comprising such sequence are particularly desirable according to this aspect.

(226) Furthermore, without being bound by theory, it is hypothesized that certain properties of the E protein of an insect-specific flavivirus may make the insect-specific flavivirus particularly desirable in this context. In particular, it is hypothesized that use of an amino acid sequence (i) of or derived from a protein encoded by the genome of an insect-specific flavivirus wherein the E protein has similar characteristics as an E protein of a flavivirus that is not insect-specific may be particularly desirable for the production of chimeric insect-specific flaviviruses of the invention.

(227) By way of non-limiting example, said E protein of the insect-specific flavivirus may have the same or similar disulphide bond folding pattern; the same or similar CD loop structure of the EDIII domain; or the same or similar structure of the EDI domain, or EDII domain, as a flavivirus that is not insect-specific, preferably wherein the immunogenic sequence (ii) of the protein of this aspect is of or derived from said flavivirus that is not insect specific.

(228) In certain preferred embodiments, the amino acid sequence (i) is encoded by the genome of a flavivirus that has a mosquito as a native host. Preferably, said mosquito is selected from the group consisting of Coquillettidia spp.; Aedes spp.; and Culex spp.

(229) Preferably, the insect-specific flavivirus of (i) is selected from the group consisting of Palm Creek virus (PCV); Binjari virus (BinJV); Lilly Creek virus (LiCV) and Bamaga virus (BgV). With reference to the Figures and Examples, it will be appreciated that said viruses can infect a plurality of genera and/or species of insect cells. In particular regard to BinJV, it will be appreciated that the E protein of this insect-specific flavivirus has similar characteristics as certain flaviviruses that are not insect-specific (such as Zika virus, West Nile virus, and Dengue virus) amino acid sequence of or derived from which viruses are preferred for use as immunogenic sequences (ii) of the protein of this aspect, as hereinbelow described. Specifically, the E protein of BinJV has substantially the same: disulphide bond folding pattern; structure within the CD loop of EDIII; and EDI structure surrounding the N-linked glycosylation site (notwithstanding the presence of a small deletion), as the E proteins of Zika virus, West Nile virus, and Dengue virus.

(230) In embodiments, the insect-specific flavivirus of (i) may be selected from the group consisting of Parramatta River virus (PaRV), Cell fusing agent virus (CFAV), and Karumba virus (KRBV). With reference to the Figures and Examples, it will be appreciated that infecting by said viruses is restricted to individual mosquito species or genera.

(231) In particularly preferred embodiments, (i) comprises an amino acid sequence set forth in SEQ ID NOS:5-7, or 387, or a fragment, variant, or derivative thereof. In embodiments, (i) may comprise an amino acid sequence set forth in SEQ ID NOS:17-19.

(232) It will be understood that, in certain embodiments, the amino acid sequence (i) of the isolated protein of this aspect may be of, or derived from, a plurality of insect-specific flaviviruses. By way of non-limiting example, the amino acid sequence (i) may be of a plurality of flavivirus subunit proteins, each of which is of or derived from an individual insect-specific flavivirus. Additionally or alternatively, individual subunit protein(s) may be encoded by at least a portion of the amino acid sequence (i) that is of or derived from a plurality of insect-specific flaviviruses.

(233) Immunogenic Sequences

(234) As set forth above, the immunogenic sequence (ii) of the protein of this aspect will not be encoded by the genome of an insect-specific flavivirus.

(235) Immunogenic amino acid sequences of this aspect may be any sequence capable of eliciting an immune response upon administration to an animal. In embodiments, the immune response may be either mucosal, B-lymphocyte or T-lymphocyte mediated, or a combination thereof. Without limitation, the T-lymphocyte mediated response may be a specific cytotoxic T-lymphocyte response. In certain preferred embodiments, the immunogenic sequences may induce a neutralising antibody response. Preferably, the immune response is a protective immune response.

(236) It will be appreciated that the isolated insect-specific flavivirus may include a plurality of immunogenic amino acid sequences (ii). The plurality of isolated immunogenic amino acid sequences may be a plurality of the same immunogenic amino acid sequences, or a plurality of different immunogenic amino acid sequences.

(237) It will also be understood that “spacer” amino acids may be included between one or the plurality of the immunogenic sequences or fragments thereof present in said isolated protein. Such spacer amino acid sequences need not be immunogenic themselves, but may serve to separate one or a plurality of immunogenic sequences from other components of the amino acid sequence of the isolated insect-specific flavivirus according to this aspect.

(238) In preferred embodiments, the immunogenic amino acid sequence (ii) of the protein of this aspect comprises an amino acid sequence of, or derived from, a protein encoded by the genome of a flavivirus that is not insect-specific.

(239) In preferred embodiments, the immunogenic amino acid sequence (ii) is of at least part of a structural protein of a flavivirus that is not insect-specific. Suitably, the structural protein is selected from the group consisting of a Capsid; prM; and Envelope protein. Preferably, the structural protein is a prM protein and/or an Envelope protein.

(240) Additionally or alternatively, the immunogenic amino acid sequence may be of at least part of a non-structural protein of the flavivirus. Suitably, the non-structural protein is selected from the group consisting of an NS1; NS2A; NS2B; NS3; NS4A; NS4B; and NS5 protein. In one particularly preferred alternative embodiment, the non-structural protein is NS1.

(241) In embodiments wherein the immunogenic amino acid sequence (ii) is of protein encoded by the genome of a flavivirus that is not insect-specific, preferably said flavivirus is a vertebrate-infecting flavivirus. More preferably, said flavivirus is a mammal, reptile or avian-infecting flavivirus. In one particularly preferred embodiment, said flavivirus is a human-infecting flavivirus. In one particularly preferred embodiment, said flavivirus is a crocodile-infecting flavivirus.

(242) Preferably, the immunogenic amino acid sequence (ii) is of a protein encoded by the genome of a flavivirus selected from the group consisting of Zika virus (ZIKV); West Nile virus (WNV); Dengue virus (DENY); Japanese encephalitis virus (JEV); Yellow fever virus (YFV); tick-borne encephalitis virus (TBEV), St Louis encephalitis virus (SLEV), Murray valley encephalitis virus (MVEV); Duck tembusu virus; Turkey Meningoencephalitis Virus (TMEV); Usutu virus; Sepik virus; Wesselsbron virus; Baiyangdian Virus (BYD); Sitiawan Virus (SV). Preferably, said flavivirus is selected from the group consisting of Zika virus, West Nile virus; and Dengue virus.

(243) In a preferred embodiment wherein the virus is West Nile virus, the virus is the Kunjin (KUNV) subtype of West Nile virus. In a preferred embodiment wherein the virus is Dengue virus, the virus is Dengue Virus Type 1, 2, 3 or 4.

(244) In particularly preferred embodiments, the immunogenic sequence (ii) of the isolated protein of this aspect is or comprises an amino acid sequence set forth in SEQ ID NOS:8-10, or a fragment, variant, or derivative thereof.

(245) In embodiments wherein the immunogenic sequence (ii) is of a protein encoded by the genome of a flavivirus that is not insect-specific, it is particularly preferred that, within the isolated protein of this aspect, the immunogenic sequence (ii) replaces a corresponding amino acid sequence of the insect-specific flavivirus which genome encodes the amino acid sequence (i).

(246) By way of non-limiting example, in the particularly preferred embodiment of the isolated protein of this aspect set forth in SEQ ID NO:1, as set forth in the examples, the immunogenic sequence (ii) (the prM and Envelope amino acid sequence) encoded by the genome of a human-infecting flavivirus (West Nile virus), has replaced the corresponding prM and Envelope amino acid sequence encoded by the genome of an insect-specific flavivirus (Palm Creek virus).

(247) Without being bound by theory, the inventors hypothesize that the use of an immunogenic sequence (ii) encoded by the genome of a flavivirus that is not insect-specific which replaces a corresponding amino acid sequence within a structural or non-structural protein encoded by the genome of an insect-specific flavivirus in the isolated protein of this aspect may be particularly advantageous for the invention. By way of non-limiting example, it is hypothesized that, at least in some circumstances, this may allow for improved replication of an isolated chimeric insect-specific flavivirus comprising said protein in insect cells and/or the inducement of a desirable immune response in a subject, when the isolated protein, or an isolated chimeric insect-specific flavivirus, or a related virus particle, comprising the protein, is used as or as part of a vaccine. This arrangement is also expected to facilitate the native folding of the immunogenic sequence (ii), e.g. in embodiments wherein said immunogenic sequence is of an E protein and/or prM protein.

(248) In some preferred embodiments, the immunogenic sequence (ii) may be of the EDIII domain of an E protein of the isolated protein of this aspect. Suitably, in these embodiments, the isolated protein comprises an E protein that is chimeric. Preferably, the EDIII domain of the chimeric E protein is an immunogenic sequence (ii) that is of or derived from a vertebrate-infecting flavivirus, and the remainder of the E protein (including the EDI and EDII domains) is of the amino acid sequence (i) encoded by the genome of an insect-specific flavivirus. Alternatively, the EDI and/or the EDII domain of the chimeric E protein may be an immunogenic sequence (ii) that is of or derived from a vertebrate infecting flavivirus, and the remainder of the E protein may be of the amino acid sequence (i) encoded by the genome of an insect-specific flavivirus.

(249) In some preferred embodiments, the immunogenic sequence (ii) may be of a prM protein of the isolated protein of this aspect.

(250) With reference to the Examples, it will be appreciated that isolated proteins of this aspect wherein the immunogenic sequence (ii) is of the EDIII domain of the E protein and/or the prM protein of the isolated protein, may have particularly desirable properties in regard to specificity of the immunogenic sequence. As such, these embodiments of the isolated protein of this aspect may be particularly desirable in the context of diagnostic applications, as hereinbelow described.

(251) Furthermore, it will be appreciated that use of an immunogenic sequence (ii) that is of the EDIII domain and/or the prM protein of the isolated protein of this aspect may facilitate improved or enhanced expression of the immunogenic EDIII domain and/or prM protein, as compared to certain existing recombinant protein expression strategies. As will be understood by the skilled person, recombinant flavivirus prM protein in particular is difficult to express in large quantities using traditional recombinant expression strategies, as it is a membrane anchored protein.

(252) It will nevertheless be understood that the immunogenic sequence (ii) of the isolated protein of this aspect need not necessarily replace a corresponding amino acid sequence of the insect-specific flavivirus which genome encodes the amino acid sequence (i). For example, the immunogenic sequence (ii) may be an addition or insertion to the amino acid sequence (i). By way of elaboration, the immunogenic sequence may be attached to the amino or carboxy terminal of a structural or non-structural protein comprising the amino acid sequence (i), or be inserted within a structural or non-structural protein comprising the amino acid sequence (i).

(253) It will be further appreciated that, although the use of an immunogenic sequence (ii) that is of, or derived from, a protein encoded by the genome of a flavivirus that is not insect-specific is particularly preferred, the use of any other suitable immunogenic amino acid sequences (ii) also falls within the scope of this aspect.

(254) Generally, suitable other sequences for use as the immunogenic amino acid sequence (ii) of the isolated protein of this aspect may include amino acid sequence derived from, of, or corresponding to an immunogen from a pathogenic organism such as a virus, a bacteria, a fungi and a parasite; a cancer immunogen; an allergic reaction immunogen (i.e., an allergen); a transplantation immunogen; or an autoantigen, although without limitation thereto.

(255) Preferably, such other suitable immunogenic amino acid sequences are of a pathogenic organism that causes or is related to or associated with an infectious disease, disorder, or condition of an animal Preferably the animal is a vertebrate, preferably an avian; reptile; or mammal, preferably a human. Said pathogenic organisms include, but are not limited to viral; bacterial; fungal; mycobacterial; and parasitic organisms.

(256) Particularly preferred other suitable immunogenic amino acid sequences are amino acid sequences from a virus. Further to the preferred embodiments wherein the immunogenic amino acid sequence (ii) is of a flavivirus that is not insect-specific, the invention encompasses immunogenic amino acid sequences (ii) of any member of the positive (+) sense RNA Virus group including (and without limitation thereto) any member of the family Astroviridae inclusive of an astrovirus (e.g., a human astrovirus) and an arterivirus (e.g., an equine arteritis virus); any member of the family Caliciviridae inclusive of a Norwalk virus, a Hepatitis E virus; any member of the family Coronaviridae inclusive of Corona Virus and SARS and a torovirus; any member of the family Picornaviridae inclusive of an enterovirus, a rhinovirus (e.g. a human rhinovirus 1A), a hepatovirus (e.g. a hepatitis A virus), a cardiovirus (e.g. a encephalomyocarditis virus) and an aphtovirus (e.g. foot-and-mouth disease virus); any member of the family Togaviridae inclusive of an alphavirus (e.g., a Sindbis virus) and a rubivirus (e.g. a rubella virus).

(257) The invention also encompasses immunogenic amino acid sequences (ii) of any member of the negative (−) sense RNA virus group including (and without limitation thereto) any member of the family Filoviridae inclusive of a filovirus (e.g. Marburg virus, Ebola virus); any member of the family Paramyxoviridae inclusive of a paramyxovirus (e.g. a human parainfluenza virus 1), a morbillivirus (e.g. a measles virus), a rubulavirus (a mumps virus), a Hendra virus and a Nipah virus; any member of the family Pneumovirinae inclusive of a pneumovirus (eg. a human respiratory syncytial virus); any member of the family Rhabdoviridae inclusive of a vesiculovirus (e.g. a vesicular stomatitis virus, Indiana virus), a lyssavirus (e.g. a rabies virus) and an ephemerovirus (e.g. a bovine ephemeral fever virus); any member of the ambisense RNA virus group inclusive of any member of the family Arenaviridae such as an arenavirus (e.g. lymphocytic choriomeningitis virus); any member of the family Bunyaviridae inclusive of a bunyavirus (e.g. Bunyamwera virus) and a hantavirus (e.g. a Hantaan virus); any member of the family Orthomyxoviridae inclusive of an influenzavirus A (such as an influenza A virus, an avian influenza A virus), an influenzavirus B (such as an influenza B virus), an influenzavirus C (such as an influenza C virus) and a “Thogoto-like viruses” (e.g. Thogoto virus).

(258) The invention also encompasses immunogenic amino acid sequences (ii) of any member of the dsRNA Viruses group including (and without limitation thereto) any member of the family Birnaviridae inclusive of an aquabirnavirus (e.g., an infectious pancreatic necrosis virus) and an avibirnavirus (e.g., infectious bursal disease virus); any member of the family Reoviridae inclusive of an orthoreovirus (e.g., a reovirus 3), a orbivirus (e.g., a bluetongue virus 1), a rotavirus, a coltivirus (e.g., a Colorado tick fever virus and an aquareovirus.

(259) The invention also encompasses immunogenic amino acid sequences (ii) of any member of the RNA Reverse Transcribing Viruses group including any member of the family Retroviridae inclusive of a mammalian type B retrovirus (e.g. a mouse mammary tumor virus), a mammalian type C retrovirus (e.g. a murine leukemia virus), an avian type C retrovirus (e.g. a avian leukosis virus), a type D retrovirus (eg a Mason-Pfizer monkey virus), a BLV-HTLV retrovirus (e.g. a bovine leukemia virus), a lentivirus (e.g. a human immunodeficiency virus 1) and a spumavirus (e.g. a human spumavirus). The invention also encompasses immunogenic amino acid sequences (ii) of any member of the dsDNA Viruses group including (and without limitation thereto) any member of the family Adenoviridae inclusive of a mastadenovirus (eg, a human adenovirus) and an aviadenovirus (eg, a fowl adenovirus), although without limitation thereto; any member of the family Herpesviridae inclusive of an Alphaherpesvirinae such as, but not limited to, a simplexvirus (e.g., a human herpesvirus 1) and a varicellovirus (e.g. a human herpesvirus 3); a Betaherpesvirinae such as, but not limited to, a cytomegalovirus (e.g., human herpesvirus 5), a muromegalovirus (e.g., a mouse cytomegalovirus 1), a roseolovirus (e.g., a human herpesvirus 6); a Gammaherpesvirinae such as, but not limited to, a lymphocryptovirus (e.g., a human herpesvirus 4), a rhadinovirus (e.g., an ateline herpesvirus 2); any member of the family Papillomaviridae inclusive of a papillomavirus, preferably human papillomavirus, and preferably subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, although without limitation thereto; any member of the family Iridoviridae inclusive of a ranavirus and such as, epizootic haematopoietic necrosis virus, but not limited to; any member of the family Polyomaviridae inclusive of a polyomavirus and preferably murine polymavirus; any member of the family Poxviridae inclusive of an orthopoxvirus (e.g., a vaccinia virus), a parapoxvirus (e.g., a orf virus), an avipoxvirus (e.g., a fowlpox virus), an capripoxvirus (e.g., a sheep pox virus), a leporipoxvirus (e.g., a myxoma virus) and a suipoxvirus (e.g., a swinepox virus).

(260) The invention also encompasses immunogenic amino acid sequences (ii) of any member of any member of the ssDNA Viruses group including (and without limitation thereto) any member of the family Parvoviridae inclusive of a parvovirus (e.g., Rheumatoid arthritis virus, B19).

(261) The invention also encompasses immunogenic amino acid sequences (ii) of any member of the DNA Reverse Transcribing Viruses group including any member of the family Hepadnaviridae inclusive of an orthohepadnavirus (e.g. a hepatitis B virus) and an avihepadnavirus (e.g. a duck hepatitis B virus), although without limitation thereto.

(262) Nucleic Acids Encoding Amino Acid Sequences of Isolated Proteins

(263) A related aspect of the invention provides an isolated nucleic acid encoding the amino acid sequence of the isolated protein of the preceding aspect.

(264) In certain particularly preferred embodiments, the isolated nucleic acid of this aspect is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NOS:1-4 or SEQ ID NOS:32, 389, 391 or 395 or a fragment, variant, or derivative thereof.

(265) In certain embodiments, the isolated nucleic acid of this aspect is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NOS:20, 22, 24, 26, 28, 30, 384, 393, 397, or 402-405, or a fragment or variant thereof.

(266) In certain embodiment, the isolated nucleic acid of this aspect comprises the nucleotide sequence set forth in SEQ ID NOS:11, 12, 13, 14, 21, 23, 25, 26, 27, 29, 31, 33, 385, 386, 388, 390, 392, 394, 396, or 398-401.

(267) The isolated nucleic acid of this aspect will comprise a nucleotide sequence of an insect-specific flavivirus; and a nucleotide sequence encoding an immunogenic amino acid sequence, wherein the immunogenic nucleotide sequence is not of an insect-specific flavivirus.

(268) Preferably, the nucleotide sequence of the isolated nucleic acid of this aspect that is of the insect-specific flavivirus is of an insect-specific flavivirus capable of infecting a plurality of different insects. In certain preferred embodiments, said insect-specific flavivirus has a native host selected from the group consisting of Coquillettidia spp.; Aedes spp.; Anopheles spp.; Mansonia spp.; Toxorhynchites spp. and Culex spp.

(269) Preferably, the insect-specific flavivirus of (i) is selected from the group consisting of PCV; BJV; BgV; and LiCV. In embodiments, the insect-specific flavivirus of (i) may be selected from the group consisting of PRV; CFAV; and KRBV.

(270) In particularly preferred embodiments, the nucleotide sequence of the isolated nucleic acid of this aspect that is of the insect-specific flavivirus comprises a nucleotide sequence encoding an amino acid sequence set forth in SEQ ID NOS:5-7 or 387, or a fragment or variant thereof. Exemplary nucleotide sequences encoding the amino acid sequences set forth in SEQ ID NOS:5-7 and 387 are set forth in SEQ ID NOS:39-41 and 386, respectively.

(271) In embodiments, the nucleotide sequence of the isolated nucleic acid of this aspect that is of the insect-specific flavirus comprises a nucleotide sequence encoding an amino acid sequence set forth in SEQ ID NOS:17-19, or a fragment or variant thereof. Exemplary nucleotide sequences encoding the amino acid sequences set forth in SEQ ID NOS:17-19 are set forth in SEQ ID NOS:42-44, respectively.

(272) In preferred embodiments of the isolated nucleic acid of this aspect, the nucleotide sequence that encodes the immunogenic amino acid sequence encodes at least part of a protein of a flavivirus that is not insect-specific.

(273) In preferred embodiments, said immunogenic amino acid sequence is of at least part of a structural protein of a flavivirus that is not insect-specific. Suitably, the structural protein is selected from the group consisting of a Capsid; prM; and Envelope protein. Preferably, the structural protein is a prM protein and/or an Envelope protein.

(274) Additionally or alternatively, said nucleotide sequence encoding the immunogenic amino acid sequence may encode at least part of a non-structural protein of the insect-specific flavivirus producible by the vector. Suitably, the non-structural protein is selected from the group consisting of an NS1; NS2A; NS2B; NS3; NS4A; NS4B; and NS5 protein.

(275) Preferably, said nucleotide sequence of the isolated nucleic acid of this aspect encoding the immunogenic amino acid sequence encodes an immunogenic amino acid sequence of a flavivirus selected from the group consisting of ZIKV; WNV; Dengue; JEV; YFV; TBEV, SLEV, MVEV; Duck tembusu virus; TMEV; Usutu virus; Sepik virus; Wesselsbron virus; BYD; and SV. In a particularly preferred embodiment, said virus is selected from the group consisting of West Nile virus; Zika virus; and Dengue virus.

(276) In particularly preferred embodiments, said nucleotide sequence that encodes the immunogenic amino acid sequence is or comprises a nucleotide sequence encoding an amino acid set forth in SEQ ID NOS:8-10, or a fragment or variant thereof. Exemplary nucleotide sequences encoding the amino acid sequences set forth in SEQ ID NOS:8-10 are set forth in SEQ ID NOS:43-45, respectively.

(277) It will be understood that the isolated nucleic acid according to this aspect may, but need not necessarily, be capable of replicating an isolated chimeric insect-specific flavivirus comprising the isolated protein of the directly preceding aspect. As used herein, an isolated nucleic acid that is “capable of replicating” an isolated chimeric insect-specific flavivirus will be understood to be a nucleic acid that can, at least under certain circumstances, be used to produce a complete, functioning, isolated chimeric insect-specific flavivirus.

(278) As will be readily understood by the skilled person, viral replication occurs in a suitable host cell relying upon the host cell machinery. For an overview of viral replication, the skilled person is directed to Carter and Saunders, Virology: Principles and Applications, John Wiley & Sons Inc (New York, 2013), incorporated herein by reference. Generally, viral replication involves steps of (a) expression of viral proteins, including structural and non-structural proteins, from the viral genetic material; (b) replication of the viral genetic material; and (c) packaging of the replicated viral genetic material into the viral structural proteins.

(279) For the purposes of this invention, an isolated nucleic acid that is “capable of replicating” an isolated chimeric insect-specific flavivirus will be understood to refer to an isolated nucleic acid that, when combined with a suitable host cell, results in the replication of the flavivirus. Examples of approaches to combine the isolated nucleic acid with the suitable host cell include direct transfection of the host cell with the isolated nucleic acid, including stable and transient transfection as are well known in the art, and/or transcription of the nucleic acid within the host cell, e.g. from a suitable vector as hereinbelow described.

(280) Also provided according to the invention are genetic constructs comprising the isolated nucleic acid of this aspect. Suitably, the genetic construct may be in the form of, or comprise genetic components of, a plasmid, bacteriophage, a cosmid, a yeast or bacterial artificial chromosome as are well understood in the art. Genetic constructs may be suitable for maintenance and propagation of an isolated nucleic acid in bacteria or other host cells, for manipulation by recombinant DNA technology and/or expression of the nucleic acid or an encoded protein as herein described.

(281) For the purposes of host cell expression, the genetic construct may be an expression construct. Suitably, the expression construct comprises one or more nucleic acids or variants described herein operably linked to one or more additional sequences in an expression vector.

(282) An “expression vector” may be either a self-replicating extra-chromosomal vector such as a plasmid, or a vector that integrates into a host genome.

(283) By “operably linked” is meant that said additional nucleotide sequence(s) is/are positioned relative to the nucleic acid of the invention preferably to initiate, regulate or otherwise control transcription.

(284) In one embodiment, the additional nucleotide sequences are regulatory sequences. Regulatory nucleotide sequences will generally be appropriate for the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells.

(285) Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences.

(286) Constitutive or inducible promoters as known in the art may be used for genetic constructs of the invention. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter.

(287) In certain embodiments, the genetic construct of this aspect may comprise one or more small RNA target sequences.

(288) As used herein, “small RNA” will be understood to refer to small, non-coding RNA molecules that have the capacity to bind to and regulate the expression, translation and/or replication of other nucleic acid molecules. The skilled person is directed to Ipsaro, J. J., & Joshua-Tor, L., 2015, Nature Struc. & Mol. Biol. 22 20 for a summary of summary of small RNAs. By way of non-limiting example, the skilled person will appreciate that small RNAs encompasses molecules referred to as ‘microRNA’, ‘miRNA’, or ‘siRNA’. However, it will be understood that all similar such molecules are included within the scope of small RNA as used herein.

(289) A “small RNA target” will be understood to refer to a nucleotide sequence that is bound by or otherwise interacts with a small RNA, to facilitate regulation of a nucleic acid comprising said sequence.

(290) In certain preferred embodiments, the small RNA target is a microRNA target.

(291) In embodiments wherein the genetic construct includes a small RNA target, the small RNA target will suitably be adapted to regulate or otherwise modulate or control production or translation of a protein of the preceding aspect that is encoded by the genetic construct, and/or an isolated chimeric insect-specific flavivirus comprising said protein, in a cell. Preferably, the cell is an insect cell. Preferably the insect cell is a mosquito cell.

(292) By way of example, the small RNA target may be adapted to be bound by small RNAs known to be produced in particular cell types, such as mosquito cells (although without limitation thereto). It will be appreciated that binding of the small RNA target in said cell types will typically constrain or prevent replication of a genetic construct comprising the small RNA target, a protein encoded by said genetic construct, and/or a chimeric insect-specific flavivirus comprising said nucleic acid and/or protein, in the cell.

(293) In particularly preferred embodiments, the small RNA target is adapted to constrain or prevent translation of a protein of the preceding aspect, and/or replication of an isolated chimeric insect-specific flavivirus comprising said protein, in the midgut of a mosquito.

(294) Host cells comprising genetic constructs as described above are also provided according to the invention. The host cell will typically be for nucleic acid and/or protein expression, and may be any suitable prokaryotic or eukaryotic cell, as are well-known in the art. For an overview of strategies for recombinant expression in host cells, the skilled person is directed to Lorence, Recombinant Gene Expression: Reviews and Protocols, Human Press (2011), incorporated herein by reference.

(295) Isolated Chimeric Insect-Specific Flaviviruses

(296) A further aspect of the invention provides an isolated chimeric insect-specific flavivirus comprising the isolated protein; and the isolated nucleic acid that is capable of replicating the isolated chimeric insect-specific flavivirus, of the preceding aspects.

(297) As hereinabove described, the isolated chimeric insect-specific flavivirus will be capable of infecting a suitable insect host and/or growing and replicating in suitable insect cell lines, but will not infect and/or grow or replicate, or will at least demonstrate substantially restricted ability to infect and/or grow or replicate, in at least wild type vertebrate cell lines.

(298) In embodiments, the isolated chimeric insect-specific flavivirus comprises a genome consisting of or comprising a nucleotide sequence set forth in SEQ ID NOS: 11, 12, 13, 14, 21, 23, 25, 26, 27, 29, 31, 33, 385, 386, 388, 390, 392, 394, 396, or 398-401, or a fragment or variant thereof; and/or an isolated protein consisting of or comprising an amino acid sequence encoded by a nucleotide sequence set forth in SEQ ID NOS: 11, 12, 13, 14, 21, 23, 25, 26, 27, 29, 31, 33, 385, 386, 388, 390, 392, 394, 396, or 398-401, or a fragment or variant thereof.

(299) In embodiments, the isolated chimeric insect-specific flavivirus comprises an isolated protein consisting of or comprising an amino acid sequence set forth in SEQ ID NOS:1-4, 32, 389, 391 or 395 or a fragment, variant, or derivative thereof; and/or a genome consisting of or comprising a nucleotide sequence set forth in SEQ ID NOS:11-14 or 33, 388, 390, or 394, or a fragment or variant thereof.

(300) In embodiments, the isolated chimeric insect-specific flavivirus may comprise an isolated protein consisting of or comprising an amino acid sequence set forth in SEQ ID NOS:20, 22, 24, 26 28, 30, 384, 393, 397, or 402-405, or a fragment, variant, or derivative thereof; and/or a genome consisting of or comprising a nucleotide sequence set forth in SEQ ID NOS:21, 23, 25, 27, 29, 31, 385, 392, 396, 398, 399, or a fragment or variant thereof.

(301) Vectors Capable of Replicating Insect-Specific Flaviviruses

(302) In a further aspect, the invention provides a vector comprising:

(303) (i) the isolated nucleic acid of the above described aspect; and

(304) (ii) an insect-specific promoter operably connected to the isolated nucleic acid (i).

(305) The term “operably connected” is used in this context to mean that the insect-specific promoter (ii) is positioned to initiate, regulate or otherwise control transcription of (i). Suitably, the insect-specific promoter is capable of controlling transcription of (i) in an insect cell.

(306) In particularly preferred embodiments, the vector of this aspect is or comprises a nucleotide sequence set forth in SEQ ID NOS:11-14 or 33, or a fragment or variant thereof. In embodiments, the vector of this aspect is or comprises a nucleotide sequence set forth in SEQ ID NOS:21, 23, 25, 27, 29, 31, or 385.

(307) In preferred embodiments of this aspect, the isolated nucleic acid (i) is capable of replicating an isolated chimeric insect-specific flavivirus according to the directly preceding aspect.

(308) Without limitation thereto, preferred vectors of this aspect of the invention are particularly adapted for transfection into insect cells, wherein (i) is transcribed under the control of (ii), and a chimeric insect-specific flavivirus replicable by (i) subsequently replicates within the insect cell.

(309) In some embodiments, the vector comprises one or more small RNA target sequences as hereinabove described, for regulation of replication of an isolated chimeric insect-specific flavivirus in one or more cells. Preferably, said cells are insect cells, preferably mosquito cells. Preferably, the one or more small RNA sequences prevent or constrain replication of the chimeric insect-specific flavivirus in one or more cells of the midgut of a mosquito. Preferably, the inclusion of the small RNA target sequence in the vector of this aspect prevents or constrains replication of the chimeric insect-specific flavivirus in a mosquito, upon ingestion of the vector or a chimeric insect-specific flavivirus comprising the vector, by a mosquito.

(310) Insect-Specific Promoters

(311) In preferred embodiments of this aspect, the insect-specific promoter (ii) of the vector is of an insect virus.

(312) As set forth in the examples, the inventors have discovered that the use of an insect-specific promoter from an insect virus can facilitate transcription to initiate replication of insect-specific flaviviruses in insect cells upon transfection of the insect cells with a vector encoding the ISF.

(313) In certain preferred embodiments, the insect-specific promoter of (ii) is of an insect virus selected from the group consisting of Orgyia pseudotsugata multicapsid nucleopolyhedrosis virus (OpMNPV); Autographa californica nucleopolyhedrovirus (AcMNP); and Spodoptera exigua multiple nucleopolyhedrovirus (SeMNPV).

(314) In certain preferred embodiments, the insect-specific promoter of (ii) is a promoter of an insect virus gene selected from the group consisting of an immediate-early 2 (IE2) gene; a polyhedrin gene; a p10 gene; and an orf46 gene.

(315) In preferred embodiments, the insect promoter (ii) is or comprises a nucleotide sequence set forth in SEQ ID NOS:15-16 or SEQ ID NOS:382-383.

(316) In certain particularly preferred embodiments, the insect promoter comprises the nucleotide sequence of the OpIE2 promoter set forth in SEQ ID NO:15, or a fragment or variant thereof. Preferably, the insect promoter comprises a fragment of the nucleotide sequence of the OpIE2 promoter set forth in SEQ ID NO:15. Preferably, said fragment features a deletion of one or more consecutive nucleotides relative to SEQ ID NO:15. Preferably said one or more consecutive nucleotides are located 3′ of the transcriptional start site of SEQ ID NO:15. Preferably, said fragment features of deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 nucleotides from the 3′ end of SEQ ID NO:15.

(317) In one particularly preferred embodiment, the insect promoter of (ii) comprises SEQ ID NO:16, which is referred to herein as OpIE2-CA. With reference to the examples, it will be appreciated that use of the insect promoter set forth in SEQ ID NO:16 resulted in particularly effective replication of insect-specific flaviviruses in insect cells when transcription of the virus was driven by the promoter of a vector of this aspect.

(318) Methods of Producing Vectors

(319) The invention further provides a method of producing a vector, the method including the step of operably connecting the isolated nucleic acid of the previously described aspect with an insect-specific promoter, to thereby produce the vector.

(320) Preferably, the vector produced according to the method of this aspect is the vector of the directly preceding aspect.

(321) In preferred embodiments, the method of producing a vector according to this aspect includes the step of joining at least two nucleic acids using a nucleic acid sequence amplification technique, to thereby produce the vector.

(322) As used herein “nucleic acid sequence amplification” includes but is not limited to techniques such as polymerase chain reaction (PCR) as for example described in Chapter 15 of CURRENT PROTOCOLS IN MOLECULAR BIOLOGY Eds. Ausubel et al. (John Wiley & Sons NY USA 1995-2001); strand displacement amplification (SDA); rolling circle replication (RCR) as for example described in International Application WO 92/01813 and International Application WO 97/19193; nucleic acid sequence-based amplification (NASBA) as for example described by Sooknanan et al. 1994, Biotechniques 17 1077; ligase chain reaction (LCR) as for example described in International Application WO89/09385 and Chapter 15 of CURRENT PROTOCOLS IN MOLECULAR BIOLOGY supra; Q-β replicase amplification as for example described by Tyagi et al., 1996, Proc. Natl. Acad. Sci. USA 93 5395; and helicase-dependent amplification as for example described in International Publication WO 2004/02025.

(323) In a particularly preferred embodiment, the nucleic acid sequence amplification technique is a Circular Polymerase Extension Cloning (CPEC) technique, as described in Quan and Tian (2009) PLOS ONE, 4(7): e6441, incorporated herein by reference.

(324) It will be appreciated that CPEC, while using a PCR protocol, can achieve ligation of fragments in a single cycle of PCR without amplification, in a strict sense, occurring. As such, as used herein, a “nucleic acid sequence amplification” technique will be understood to encompass a protocol capable of amplifying a nucleic acid, but that does not necessarily result in amplification sensu stricto.

(325) Preferably, the method of producing a vector according to this aspect includes the step of joining a nucleic acid comprising the insect-specific promoter with at least one nucleic acid of the previously described aspect.

(326) In preferred embodiments, the method includes the step of joining a nucleic acid comprising the insect-specific promoter with a plurality of nucleic acids which together form a preferred nucleic acid of the previously described aspect. Preferably, said nucleic acid is capable of replicating a chimeric insect-specific flavivirus.

(327) In these embodiments, preferably, each of the plurality of nucleic acids encodes at least part of a protein of the chimeric insect-specific flavivirus. The components of the chimeric insect-specific flavivirus suitably include structural and non-structural insect-specific flavivirus proteins (as hereinabove described); and an immunogenic amino acid sequence.

(328) The immunogenic sequence will be in a suitable form as hereinabove described. In preferred embodiments, the immunogenic sequence is of one or more structural or non-structural proteins of a flavivirus that is not insect-specific. In particularly preferred embodiments, the immunogenic sequence is of one or more structural proteins of a flavivirus that is not insect-specific.

(329) Preferably, each of the plurality of nucleic acids that is joined according to the method of this aspect comprises nucleotide sequence overlap with respect to an adjacent nucleic acid. With reference to the examples, it will be appreciated that such an arrangement can facilitate effective joining of the nucleic acids using a nucleic acid amplification technique, such as CPEC.

(330) With reference to the examples, it will be appreciated that particularly preferred vectors of the invention, such as the vector comprising the nucleotide sequence set forth in SEQ ID NO:11, were constructed by joining five nucleic acids using a CPEC technique, the nucleic acids respectively comprising:

(331) (I) a nucleic acid comprising an insect promoter flanked by respective portions of the 3′ and 5′ UTRs of Palm Creek virus;

(332) (II) a nucleic acid encoding a portion of the 5′ UTR, and the Capsid protein of Palm Creek virus, and prM; and Envelope proteins of West Nile virus;

(333) (III) a nucleic acid encoding NS1; NS2A; and NS2B proteins of Palm Creek virus;

(334) (IV) a nucleic acid encoding NS3; NS4A; and NS4B flavivirus proteins of Palm Creek virus; and

(335) (V) a nucleic acid encoding NS5 protein and a portion of the 3′ UTR of Palm Creek virus,

(336) wherein:

(337) (I) comprises nucleotide sequence overlap with (V) and (II);

(338) (II) comprises nucleotide sequence overlap with (I) and (III);

(339) (III) comprises nucleotide sequence overlap with (II) and (IV);

(340) (IV) comprises nucleotide sequence overlap with (III) and (V); and

(341) (V) comprises nucleotide sequence overlaps with (IV) and (I).

(342) It will be appreciated that, in the particularly preferred embodiments illustrated in Example 8, the immunogenic amino acid sequence encoded by the vector is in the form of the prM and Envelope proteins encoded by (II), and the amino acid sequence of the insect-specific flavivirus is in the form of the Capsoid protein encoded by (II) and the non-structural proteins encoded by (III)-(V).

(343) A related aspect provides a vector produced according to the method of this aspect.

(344) Proteins and Chimeric Insect-Specific Flaviviruses Produced from Vectors

(345) Further aspects of the invention provide an isolated protein or isolated chimeric insect-specific flavivirus, respectively, produced from a vector encoding according to the directly preceding aspects.

(346) An isolated protein may be produced from said vector by any suitable approach, such as hereinabove described in relation to expression vectors generally.

(347) Typically, the production of an isolated chimeric insect-specific flavivirus from said vector will require transfection of a suitable cell with the vector, wherein transcription of the nucleotide sequence of the previously described aspect with is capable of replicating a chimeric insect-specific flavivirus occurs, followed by replication of the insect-specific flavivirus in the host cell.

(348) As hereinabove described, chimeric insect-specific flaviviruses of the invention do not replicate, or at least demonstrate substantially restricted replication in at least wild type vertebrate cells. As such, cells used for production of the isolated insect-specific flavivirus according to this aspect will typically be insect cells. However, at least for some ISFs, it has been demonstrated that some degree (typically trace amounts) of replication can occur in certain mutant vertebrate cells (e.g. Tree et al. (2016) Virology, 497, 81-91, incorporated herein by reference). As such, in some cases, production of insect-specific flaviviruses according to the method of this aspect may be performed by transfection of suitably mutant non-insect cells, e.g. mutant vertebrate cells.

(349) Methods of Producing Chimeric-Insect Specific Flaviviruses from Vectors Using Insect Cells

(350) A further aspect of the invention provides a method of producing an isolated chimeric insect-specific flavivirus comprising an isolated protein of the above-described aspect, the method including the steps of:

(351) (a) combining a vector comprising (i) a nucleotide sequence capable of replicating a chimeric insect-specific flavivirus comprising the isolated protein of above-described aspect; and (ii) an insect-specific promoter operably connected to (i), with an insect cell; and

(352) (b) allowing the chimeric insect-specific flavivirus replicable by (i) to replicate in the insect cell,

(353) to thereby produce the isolated chimeric insect-specific flavivirus.

(354) Suitably, combining the vector with the insect cell according to this aspect is in the form of transfection of the insect cell with the vector.

(355) In some preferred embodiments, the insect cell according to this aspect is a mosquito cell. In preferred embodiments, the mosquito cell is an Aedes albopictus cell, preferably C6/36 or C7/10.

(356) In a particularly preferred embodiment, the mosquito cell is a C3/36 cell.

(357) In some preferred embodiments, the insect cell according to this aspect is a fly cell. Preferably, the fly cell is a fruit fly cell, preferably a Drosophila cell. Preferably, the Drosophila cell is an S2 cell.

(358) In preferred embodiments of the method of this aspect, the flavivirus is produced in the insect cell at a titre of at least: 10.sup.4/ml; 10.sup.5/ml; 10.sup.6/ml; 10.sup.7/ml; or 10.sup.8/ml. In one particularly preferred embodiment, the flavivirus is produced in the insect cell at a titre of greater than 10.sup.7/ml.

(359) As set out in the examples, certain preferred vectors of the invention comprising a nucleotide sequence capable of replicating chimeric insect-specific flavivirus comprising ISF virus proteins and an immunogenic sequence in the form of proteins of a flavivirus that is not insect-specific were produced by transfection of insect cells with the vector. Subsequently, substantial replication of the chimeric insect-specific flavivirus in the insect cells was observed.

(360) By way of example, for PCV/WNV.sub.KUN-prME (SEQ ID NO:1), the isolated chimeric insect-specific flavivirus was produced at a titre of 1.7×10.sup.6/ml. For PCV/ZIKA-prME (SEQ ID NO:2), the isolated chimeric insect-specific flavivirus was produced at a titre of 3.9×10.sup.7/ml. For PCV/DENV2-prME (SEQ ID NO:3), the isolated chimeric insect-specific flavivirus was produced at a titre of 3.6×10.sup.5/ml.

(361) A related aspect provides an isolated chimeric insect-specific flavivirus produced according to the method of this aspect.

(362) Modified Chimeric Insect-Specific Flaviviruses, and Proteins and Nucleic Acids Thereof

(363) A further aspect of the invention provides a method of modifying a chimeric insect-specific flavivirus, a protein of a chimeric insect-specific flavivirus, and/or or a nucleic acid of a chimeric insect-specific flavivirus, including the step of replicating a chimeric insect-specific flavivirus in a cell, whereby one or more mutations are incorporated into the chimeric insect-specific flavivirus, a protein thereof, and/or a nucleotide sequence thereof, to thereby modify the chimeric insect-specific flavivirus, protein thereof, and/or nucleic acid thereof.

(364) Preferably, the step of replicating the chimeric insect-specific flavivirus according to the method of this aspect includes a plurality of replication cycles. Said plurality of replication cycles may suitably be in the form of ‘serial passaging’ of the chimeric insect-specific flavivirus, as is known in the art.

(365) Preferably, the chimeric insect-specific flavivirus is replicated in an insect cell, preferably a mosquito cell, such as herein described, e.g. C6/36 or C7/10 cells, although without limitation thereto.

(366) Preferably, the method of this aspect improves or enhances efficiency of replication of the chimeric insect specific flavivirus in one or more cells. Preferably, said one or more cells are insect cells, preferably mosquito cells.

(367) With reference to Example 18, it will be appreciated that serial passaging of a chimeric insect-specific flavivirus as described herein in mosquito cells resulted in accumulation in mutations in the nucleotide sequence of the chimeric insect-specific flavivirus (cf. SEQ ID NOS:400 and 401). Additionally, as set forth in FIG. 86, increased efficiency of replication of serially passaged chimeric insect-specific flaviviruses in mosquito cells was observed.

(368) Related aspects of the invention provide isolated modified chimeric-insect specific flaviviruses, isolated proteins, and isolated nucleic acids produced according to the method of this aspect.

(369) Compositions Comprising Isolated Proteins and/or Chimeric Insect-Specific Flaviviruses

(370) Still another aspect of the invention provides a composition comprising an isolated protein and/or an isolated chimeric insect-specific flavivirus of the preceding aspects.

(371) In some embodiments of this aspect, the composition is a pharmaceutical composition. In these embodiments, the one or more carriers, diluents, or excipients will be pharmaceutically acceptable carriers, diluents, or excipients.

(372) By “pharmaceutically-acceptable carrier, diluent or excipient” is meant a solid or liquid filler, diluent or encapsulating substance that may be safely used in systemic administration to a subject.

(373) Depending upon the particular route of administration, a variety of carriers, well known in the art, may be used. These carriers may be selected from the group including sugars, starches, cellulose and its derivatives, malt, gelatine, talc, calcium sulphate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline and salts such as mineral acid salts including hydrochlorides, bromides and sulphates, organic acids such as acetates, propionates and malonates and pyrogen-free water. A useful reference describing pharmaceutically acceptable carriers, diluents and excipients is Remington's Pharmaceutical Sciences (Mack Publishing Co. N.J. USA, 1991) which is incorporated herein by reference.

(374) Dosage forms of compositions according to this aspect include tablets, dispersions, suspensions, injections, solutions, oils, syrups, troches, capsules, suppositories, aerosols, transdermal patches and the like. These dosage forms may also include injecting or implanting controlled releasing devices designed specifically for this purpose or other forms of implants modified to act additionally in this fashion. Controlled release of the therapeutic agent may be effected by coating the same, for example, with hydrophobic polymers including acrylic resins, waxes, higher aliphatic alcohols, polylactic and polyglycolic acids and certain cellulose derivatives such as hydroxypropylmethyl cellulose. In addition, the controlled release may be effected by using other polymer matrices, liposomes and/or microspheres.

(375) Compositions of the present invention suitable for enteral, oral or parenteral administration may be presented as discrete units such as capsules, sachets or tablets each containing a pre-determined amount of one or more therapeutic agents of the invention, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association one or more agents as described above with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the agents of the invention with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

(376) Preferably, the pharmaceutical composition of this aspect is a vaccine.

(377) In some embodiments, the composition of this aspect is a diagnostic composition. The diagnostic composition may be for in vivo or in vitro use. Preferably, the diagnostic composition is for in vitro use.

(378) The diagnostic composition may comprise one or more buffers, solutions, blocking agents, and/or detection reagents as are well known in the art. In some embodiments, the diagnostic composition may be in kit form. Kits may include the isolated protein and/or isolated chimeric insect-specific flavivirus of the preceding aspects and one or more of detection reagents (e.g enzymes and substrates, digoxigenin); secondary antibodies (optionally labelled); buffers, solutions and blocking agents; and/or labels selected from a group including an enzyme, a fluorophore, a chemiluminescent molecule, biotin, radioisotope or any other suitable label. Examples of suitable enzyme labels useful in the present invention include alkaline phosphatase, horseradish peroxidase, luciferase, β-galactosidase, glucose oxidase, lysozyme, malate dehydrogenase and the like. The enzyme label may be used alone or in combination with a second enzyme in solution or with a suitable chromogenic or chemiluminescent substrate.

(379) Examples of chromogens include diaminobanzidine (DAB), permanent red, 3-ethylbenzthiazoline sulfonic acid (ABTS), 5-bromo-4-chloro-3-indolyl phosphate (BCIP), nitro blue tetrazolium (NBT), 3,3′,5,5′-tetramethyl benzidine (TNB) and 4-chloro-1-naphthol (4-CN), although without limitation thereto.

(380) A non-limiting example of a chemiluminescent substrate is Luminol™, which is oxidized in the presence of horseradish peroxidase and hydrogen peroxide to form an excited state product (3-aminophthalate).

(381) Fluorophores may be fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), allophycocyanin (APC), Texas Red (TR), Cy5 or R-Phycoerythrin (RPE), although without limitation thereto.

(382) Radioisotope labels may include .sup.125I, .sup.131I, .sup.51Cr and .sup.99Tc, although without limitation thereto.

(383) Other antibody labels that may be useful include colloidal gold particles and digoxigenin.

(384) In one particularly preferred embodiment wherein the diagnostic composition is for in vitro use, the composition is for use in performing an Enzyme-Linked Immunosorbent Assay (ELISA), such as a direct or indirect ELISA. Suitably compositions for use in ELISA are well known to those skilled in the art; for an overview of ELISA reagents and protocols the skilled person is directed to Crowther, Methods in Molecular Biology, Volume 42: ELISA, Theory and Practice, Humana Press, (New Jersey, 1995), incorporated herein by reference.

(385) In one particularly preferred embodiment wherein the diagnostic composition is for in vitro use, the composition is for use in performing a lateral flow immunoassay. As will be understood by the skilled person, generally, lateral flow assays involve movement of liquid sample containing an analyte of interest, typically by capillary action, across a test strip containing molecules (such as antibodies) capable of interacting with the analyte. For an overview of lateral flow immonassays and suitable reagents and protocols, the skilled person is directed to Koczula and Gallotta (2016) Essays in Biochemistry 60: 111-120, incorporated herein by reference.

(386) Therapeutic Methods Comprising Administration of Insect-Specific Flaviviruses

(387) An aspect of the invention provides a method of eliciting an immune response in a subject, the method including the step of administering an effective amount of the isolated chimeric insect-specific flavivirus or pharmaceutical composition comprising the same as described herein to subject, to thereby elicit an immune response in the subject.

(388) By “elicits or eliciting an immune response” means inducing, activating or stimulating one or more components or elements of the immune system of an animal. The one or more components or elements of the immune system may be of the innate and/or adaptive immune systems, including cellular components (e.g lymphocytes, antigen presenting cells, dendritic cells, myelomonocytic cells) and/or molecular components (e.g. cytokines, chemokines, antibodies), although without limitation thereto.

(389) In some embodiments, the immune response is a protective immune response which is responsive to subsequent challenge or infection by a pathogen.

(390) Accordingly a related aspect of the invention provides a method of immunizing a subject against a pathogen, the method including the step of administering an effective amount of the pharmaceutical composition of the thirteenth aspect to the subject, to thereby immunize the subject against the pathogen.

(391) Another aspect of the invention provides a method of treating or preventing a disease, disorder, or condition in a subject, the method including the step of administering an effective amount of an isolated chimeric insect-specific flavivirus or pharmaceutical composition comprising the same as described herein to the subject, to thereby treat or prevent the disease, disorder or condition in the subject.

(392) Preferably, the disease, disorder, or condition according to these aspects is associated with a viral infection. Suitably, in these embodiments, the immunogenic sequence of the isolated protein or chimeric insect-specific flavivirus is of or derived from the virus with which the disease, disorder, or condition is associated.

(393) Preferably, the disease, disorder, or condition is associated with a viral infection. Preferably, the viral infection is a flaviviral infection. Preferably, the flaviviral infection is an infection with a virus selected from the group consisting of ZIKV; WNV; Dengue; JEV; YFV; TBEV, SLEV, MVEV; Duck tembusu virus; TMEV; Usutu virus; Sepik virus; Wesselsbron virus; BYD; and SV. In a particularly preferred embodiment, said virus is selected from the group consisting of West Nile virus; Zika virus; and Dengue virus.

(394) In particularly preferred embodiments said virus is selected from the group consisting of Zika virus; West Nile Virus; and Dengue virus. Preferably, the West Nile virus is KUNV. Preferably, the Dengue virus is DENV2.

(395) It will be appreciated that the pharmaceutical composition and/or methods of these aspects may be effective against a plurality of different pathogens and/or effective in treating a plurality of different diseases, disorders or conditions as described above.

(396) Accordingly, as hereinabove described, in some embodiments the isolated protein may comprise one or more additional immunogenic amino acid sequences from one or more other viruses, bacteria, protozoa, worms or other pathogens. Typically, the one or more additional immunogenic amino acid sequences would be relatively short peptide epitopes (e.g 6-20 amino acids) fused to:

(397) (i) the amino acid sequence of a protein encoded by the genome of an insect-specific flavivirus; and/or

(398) (ii) the immunogenic amino acid sequence not encoded by the genome of an insect-specific flavivirus;

(399) that do not inhibit or compromise the ability of the isolated protein to form a virus particle.

(400) Any safe route of administration may be employed according to these aspects for providing a subject with the isolated protein, chimeric insect-specific flavivirus, or pharmaceutical composition. For example, enteral, oral, rectal, parenteral, sublingual, buccal, intravenous, intra-articular, intra-muscular, intra-dermal, subcutaneous, inhalational, intraocular, intraperitoneal, intracerebroventricular, transdermal and the like may be employed.

(401) The isolated protein, chimeiric insect-specific flavivirus or pharmaceutical composition according to these aspects may be administered in a manner compatible with the dosage formulation, and in such amount as is pharmaceutically effective. The dose administered to a patient, in the context of the present invention, should be sufficient to effect a beneficial response in a patient over an appropriate period of time. The quantity of agent(s) to be administered may depend on the subject to be treated inclusive of the age, sex, weight and general health condition thereof, factors that will depend on the judgement of the practitioner.

(402) It will also be appreciated that treatment methods and pharmaceutical compositions may be applicable to prophylactic or therapeutic treatment of a subject that is an animal, inclusive of humans and non-human mammals such as livestock (e.g. horses, cattle and sheep, crocodiles, ducks, chickens, turkeys), companion animals (e.g. dogs and cats), laboratory animals (e.g. mice, rats and guinea pigs) and performance animals (e.g. racehorses, greyhounds and camels), although without limitation thereto. In one preferred embodiment, the subject is a human. In another preferred embodiment, the subject is a crocodile.

(403) A related aspect of the invention provides a method of producing an antibody with at least partial specificity against an immunogenic sequence in a subject, the method including the step of administering an isolated chimeric insect-specific flavivirus or pharmaceutical composition comprising the same as described herein to a subject, wherein an antibody is produced in the subject against the immunogenic sequence of the isolated chimeric insect-specific flavivirus, to thereby produce the antibody in the subject.

(404) Suitably, the antibody may be extracted, purified, and/or isolated from the subject after production.

(405) It will be appreciated that the directly preceding aspect may have application in the production of antibodies for research or diagnostic purposes. Without limitation, the subject may be any suitable animal subject for producing antibodies, such as a chicken, goat, guinea pig, hamster, horse, mouse, rat, sheep, or rabbit, as are well known in the art.

(406) Methods for Detecting, Identifying or Screening for Antibodies

(407) The invention also provides detection or diagnosis of antibodies that bind to the immunogenic sequence of the isolated protein or chimeric insect-specific flavivirus.

(408) Accordingly, yet a further aspect of the invention provides a method of detecting, identifying or screening for an antibody in a sample, the method including the steps of combining the diagnostic composition of the thirteenth aspect with a sample, wherein binding of an antibody in the sample to an immunogenic amino acid sequence of the isolated protein or isolated chimeric insect-specific flavivirus of the diagnostic composition facilitates detecting, identifying or screening for the antibody in the sample.

(409) Generally, the term “antibody” includes any product of the immunoglobulin gene complex, inclusive of antibody fragments.

(410) The method according to this aspect may be an in vitro method or an in vivo method.

(411) In the particular context of an in vivo method according to this aspect, a “sample” will be understood to be present in, or a component or part of the subject, whereby the diagnostic composition is administered to the subject and the antibody is detected in situ. For a non-limiting review of in vivo diagnostics, the skilled person is directed to Freise and Wu (2015) Molecular Immunology, 67(2A), 142-152, incorporated herein by reference.

(412) In embodiments where the method is an in vitro method, suitably the sample is obtained or obtainable from a subject. The sample may be a fluid sample, a cell sample, a tissue sample, a secretion, waste product or any other sample obtained or obtainable from a subject. By way of example, samples may include urine, whole blood, plasma, serum, cerebrospinal fluid, tears, perspiration, smears, skin punches, swabs, biopsies, hair, faeces, semen and sputum, although without limitation thereto.

(413) In certain preferred embodiments wherein the method of this aspect is an in vitro method, detection of the antibody is performed using an enzyme-linked immunosorbent assay (ELISA) comprising the isolated protein, chimeric insect-specific flavivirus, or composition of the preceding aspects. The ELISA may be a direct ELISA or an indirect ELISA. Reference in regard to ELISA assays is provided in Crowther, supra.

(414) In certain preferred embodiment wherein the method of this aspect is an in vitro method, detection of the antibody is performed using a lateral flow immunoassay.

(415) Preferably, the antibody of this aspect is produced in response to a viral infection. Suitably, in these embodiments, an immunogenic sequence of the isolated insect-specific flavivirus or virus particle is of or derived from the virus with which the disease, disorder, or condition is associated.

(416) Preferably, the viral infection is selected from the group consisting of ZIKV; WNV; Dengue; JEV; YFV; TBEV, SLEV, MVEV; Duck tembusu virus; TMEV; Usutu virus; Sepik virus; Wesselsbron virus; BYD; and SV.

(417) In particularly preferred embodiments said virus is selected from the group consisting of Zika virus; West Nile Virus; and Dengue virus. Preferably, the West Nile virus is KUNV. Preferably, the Dengue virus is DENV2.

(418) Also within the scope of this aspect are methods of screening for a plurality of antibodies, wherein the plurality of antibodies bind to a respective plurality of immunogenic sequences of the isolated protein or chimeric insect-specific flavivirus.

EXAMPLES

Example 1. Materials and Methods

(419) Cell Culture

(420) C6/36 (Aedes albopictus) cells were cultured at 28° C. in RPMI 1640 medium supplemented with 5% foetal bovine serum (FBS), respectively. Wild-type (WT) and interferon-α/β receptor deficient (IFNAR.sup.−/−) mouse embryonic fibroblasts (MEF) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% FBS and grown at 37° C. with 5% CO.sub.2. All media contained 50 U penicillin/mL, 50 mg streptomycin/mL and 2 mM L-glutamine

(421) Virus Culture

(422) PaRV (NC_027817.1), PCV (KC505248.1), BinJV (SEQ ID NO:40), LiCV (SEQ ID NO:386), BgV (SEQ ID NO:41), and WNV.sub.KUN (AY274504) viral stocks were propagated in C6/36 cells incubated at 28° C. for 5-7 days. Viral titres were assessed by infection of C6/36 cells with 10-fold serial dilutions of supernatant in 96-well plates and incubation for 5 days. The cell supernatant was aspirated and the monolayers fixed with acetone fixative buffer (20% acetone, 0.02% bovine serum albumin (BSA) in phosphate buffered saline (PBS)). PaRV was detected by enzyme-linked immunosorbent assay (ELISA) using the PaRV-specific monoclonal antibody (mAb) 7D11, whereas WNV.sub.KUN was detected using 4G2 [1]. Virus titres were calculated as 50% tissue culture infective dose (TCID.sub.50) using the methods previously described by Reed and Muench [2].

(423) Preparation of Monoclonal Antibodies to PaRV

(424) All animal procedures had received prior approval from The University of Queensland Animal Ethics Committee (AEC #SCMB/329/15/ARC) and where necessary were performed under ketamine:xylazil anaesthesia. Six-week old BALB/c mice (Animal Resources Centre, Murdoch, Western Australia, Australia) were immunised twice via the subcutaneous route with purified PaRV virions, along with inulin-based adjuvant Advax (Vaxine Ltd, Adelaide, Australia). Mice were kept on clean bedding and given food and water ad libitum. The mouse was boosted with PaRV virions four days prior to harvesting of the spleen. Fusion of the spleen cells with NS0 myeloma cells was performed as previously described [3]. Hybridomas secreting antibodies reactive to PaRV-infected C6/36 cells were identified by ELISA using previously described methods [4]. The target protein of each mAb was determined using PaRV-infected cell lysates in Western blot using previously published methods [4].

(425) Generation and Characterisation of a Modified OpIE2 Insect Promoter

(426) OpIE2 promoter sequences characterised by Blissard and Rohrmann [5] were synthesised as gBlocks Gene Fragments (IDT). These fragments were cloned into a previously generated plasmid containing a sequence which, when expressed by itself, linked the UTR regions of the viral genome together [6]. A Gibson Assembly Master Mix (NEB) was used. Constructs were transformed into DH5c competent E. coli, and colony PCR using Taq DNA Polymerase (NEB) conducted to screen for viable colonies. Plasmids were extracted from overnight cultures of positive colonies using a NucleoSpin Plasmid Miniprep kit (Macherey-Nagel). Extracted plasmids were then sent for sequencing at the Australian Genome Research Centre.

(427) Generation of Viruses by CPEC

(428) CPEC constructs were generated based on previously described methods [6]. Briefly, viral RNA was extracted using a NucleoSpin RNA Virus kit (Macherey-Nagel) and converted to cDNA using a qScript cDNA SuperMix (Quantabio). For each CPEC assembly, 0.1 pmol of each viral cDNA fragment was added to a Q5 PCR reaction (NEB) as per the manufacturer's instructions. Thermal cycling was carried out at 98° C. for 2 mins (one cycle), 98° C. for 30 secs, 55° C. for 30 secs, 72° C. for 6 mins (2 cycles), 98° C. for 30 secs, 55° C. for 30 secs, 72° C. for 8 mins (ten cycles). The entire CPEC reaction was transfected into cells and the passage 0 (P.sub.0) cell culture supernatants harvested and stored at −80° C., five days post-transfection.

(429) Growth Kinetics

(430) C6/36 cells seeded at a density of 1×10.sup.5 were inoculated in triplicate with a P.sub.1 CPEC-derived and P7 wild-type virus stock at a multiplicity of infection (MOI) of 0.1. After incubation at 28° C. for 1 hr the inoculum was removed and the monolayer washed three times with sterile PBS before re-incubating at 28° C. with fresh RPMI 1640 with 2% FBS. Supernatant was harvested at 2 hrs, 24 hrs, 48 hrs, 72 hrs, 96 hrs and 120 hrs. Viral titres from each time point were determined using a TCID.sub.50 assay as previously described. A two way-ANOVA was performed on the results using Graphpad Prism.

(431) IFA

(432) Cells seeded at a density of 1×10.sup.5 on glass coverslips in a 24-well plate were transfected or infected as required. Following a 72 hr incubation, the coverslips were fixed with ice cold 100% acetone and air dried before storing at −20° C. Prior to staining, coverslips were blocked with blocking buffer (0.05 M Tris/HCl (pH 8.0), 1 mM EDTA, 0.15 M NaCl, 0.05% (v/v) Tween-20, 0.2% w/v casein) for 1 hr at room temperature. Coverslips were then incubated for 1 hr with primary antibody in blocking buffer. Following 3 washes with PBS containing 0.05% Tween-20 (PBST), secondary staining was carried out with Alexafluor 488-conjugated goat anti-mouse IgG (H+L) (Invitrogen) diluted 1:1000 in blocking buffer for 1 hr. A Hoechst 33342 nuclear stain (Invitrogen) was applied for 5 mins at room temperature. Following a final 3 washes with PBST, the coverslips were mounted onto glass microscope slides using ProLong Gold Anti-fade (Invitrogen). All coverslips were viewed under the ZEISS LSM 510 META confocal microscope.

(433) Cell Transfection

(434) C6/36 cells were transfected with DNA using Effectene (Qiagen) or RNA using TransMessenger (Qiagen), as per the manufacturer's instructions. Wild-type and IFNAR.sup.−/− MEF cells were transfected using Lipofectamine LTX (Invitrogen), as per the manufacturer's instructions.

Example 2. CPEC Insect Promoter Optimisation

(435) The OpIE2 promoter originally described by Blissard and Rohrmann [5] was chosen to attempt to drive transcription of CPEC-assembled infectious cDNA in insect cells. The UTR-linker fragment as described in [6] was modified to replace the existing CMV promoter with either the complete OpIE2 promoter (SEQ ID NO:15) or a truncated version lacking the 23 nucleotides comprising the promoter 3′ tail downstream of the transcription start site (OpIE2-CA; SEQ ID NO:16) (FIG. 5). The modified OpIE2 UTR-linker was assembled by CPEC with cDNA fragments from WNV.sub.KUN and directly transfected into C6/36 cells. A TCID.sub.50 of recovered infectious virus following transfection of WNV.sub.KUN CPEC constructs into C6/36 cells indicated that passage 0 (P.sub.0) titres were approximately 100-fold higher when using the OpIE2-CA (10.sup.5.42 IU/mL) rather than the OpIE2 (10.sup.3.35 IU/mL) promoter (FIG. 5).

Example 3. Generation of Flavivirus DNA Constructs Using Circular Polymerase Extension Cloning

(436) The modified OpIE2-CA UTR-linker fragment was selected for generating a vector driving PaRV infectious cDNA, by CPEC, set forth SEQ ID NO:37 (see the schematic in FIG. 6). Primers used for constructing the PaRV CPEC vector were designed to anneal at the junctions between viral genes (FIG. 6; Table 1). CPEC-derived PaRV (PaRV.sub.CPEC) was successfully recovered from two independent transfection experiments into C6/36 cells, and the authenticity of the virus confirmed by sequencing upstream of the E protein. P.sub.0 PaRV.sub.CPEC supernatant was re-inoculated on to fresh C6/36 cells, and detected using anti-PaRV mouse serum [7] in IFA 3 days post-transfection to show successful replication of live PaRV.sub.CPEC (FIG. 6).

(437) Similarly, CPEC vectors designed to drive infectious BgV (SEQ ID NO:34); BinJV (SEQ ID NO:35); and PCV (SEQ ID NO:36) were produced. The primers for producing these respective vectors using CPEC are set forth in Table 1.

Example 4. CPEC-Derived Viruses are Phenotypically the Same as Wild Type Viruses

(438) PaRV.sub.CPEC was assessed by two methods to confirm that it was phenotypically the same as PaRV.sub.WT. In a growth kinetics assay, PaRV.sub.CPEC displayed an identical growth profile to PaRV.sub.WT, with no significant difference in the titres at any time point (two-way ANOVA). PaRV.sub.CPEC and PaRV.sub.WT replicated rapidly in the first 24 hrs (PaRV.sub.CPEC 10.sup.5.78/mL; PaRV.sub.WT 10.sup.5.86/mL), reaching a peak titre at 72 hrs (PaRV.sub.CPEC 10.sup.7.72/mL; PaRV.sub.WT 10.sup.7.91/mL), after which the virus titre plateaued (FIG. 3a). Consistent with a previous study [7], the titre of PaRV at 24 hours was significantly higher than WNV.sub.KUN, however at four days post-infection WNV.sub.KUN (10.sup.5.86/mL) produced a significantly (two-way ANOVA; P<0.001) higher titre of virus than both PaRV.sub.WT (10.sup.7.39/mL) and PaRV.sub.CPEC (10.sup.7.63/mL). Further antigenic analysis using a panel of monoclonal antibodies, that were reactive to PaRV prM or E proteins, similarly confirmed the antigenic conservation between of PaRV.sub.WT and PaRV.sub.CPEC (FIG. 8). Comparison of infectious virus derived from P0 transfections of either PaRV RNA or a PaRV CPEC reaction revealed relatively comparable titres of 10.sup.7.80/mL and 10.sup.6.97/mL, respectively after a 5 day incubation.

(439) Similar assessment was conducted for PCV.sub.CPEC. The growth kinetics of this virus are set forth in FIG. 58; with a peak titre of 10.sup.7.5/ml observed at 48 hours. Furthermore, antigenic authenticity of the virus was confirmed using monoclonal antibodies, and nucleotide sequence was confirmed by sequencing.

(440) Growth kinetics of BgV.sub.CPEC and BinJV.sub.CPEC were also assessed, with peak titres of 10.sup.7/ml and 10.sup.8.4/ml observed, respectively.

Example 5. Using CPEC to Bypass Viral Entry does not Overcome Host Restriction of PaRV in Either IFN Response-Competent or -Deficient Cells

(441) There is recent evidence that the Aedes-associated ISF, Kamiti River virus, can enter and replicate in vertebrate cells in vitro in the absence of interferon regulatory factors [8]. We examined whether PaRV, another Aedes-associated ISF, could also replicate in IFN response-deficient (IFN-α/β receptor knockout, IFNAR′) mouse embryonic fibroblasts via inoculation with PaRV, or by bypassing viral entry through transfecting with a PaRV CPEC vector driven by a CMV promoter. An IFA of inoculated MEF cells showed that there was no observable replication of PaRV in either the WT or IFNAR.sup.−/− MEFs (FIG. 9). In contrast, WNV.sub.KUN replicated readily. A TCID.sub.50 conducted on the supernatant from CPEC-transfected MEF cells indicated that no infectious PaRV was produced from either cell line, while titres of 8.5×10.sup.4 IU/mL and 3.5×10.sup.6 IU/mL were observed for WNV.sub.KUN transfected WT and IFNAR.sup.−/− MEF cells, respectively.

Example 6. Chimeric ISF Vectors not Observed to Replicate Virus

(442) Vectors as described in Example 3, but containing either the PaRV prME genes on a WNV.sub.KUN genomic backbone (WNV.sub.KUN/PaRV-prME; SEQ ID NO:31) or the WNV.sub.KUN prME genes on a PaRV genomic backbone (PaRV/WNV.sub.KUN-prME; SEQ ID NO:385) were designed. CPEC was performed and transfected into C6/36 cells. While replicates of simultaneously transfected WNV.sub.KUN and PaRV.sub.CPEC control constructs were positive for virus replication as determined by IFA 5 days post-transfection, neither WNV.sub.KUN/PaRV-prME nor PaRV/WNV.sub.KUN-prME replication was detected (FIG. 10). Passaging the P.sub.0 supernatant of the cells transfected with the chimeric CPEC constructs also failed to show any replication. The results indicated a possible incompatibility of genes between PaRV and WNV.sub.KUN.

(443) A CPEC vector containing the prME genes from CFAV isolated from Australian Aedes aegypti mosquitoes on a WNV.sub.KUN genomic backbone (WNV.sub.KUN/CFAV-prME; SEQ ID NO:27) was also produced. IFA analysis on transfected C6/36 cells indicated limited viral RNA replication and protein expression (FIG. 10), however titration and passaging of P.sub.0 supernatant indicated that no infectious virus was being produced.

Example 7. Chimeric WNV/PCV Vector Capable of Replicating Virus

(444) A further CPEC vector containing the prME genes of another Australian ISF, Palm Creek virus (PCV) [9], on a WNV.sub.KUN genomic backbone (WNV.sub.KUN/PCV-prME; SEQ ID NO:20) was also produced.

(445) The WNV.sub.KUN/PCV-prME vector successfully generated viable virus when transfected in C6/36 cells. IFA analysis of the chimeric WNV.sub.KUN/PCV-prME virus revealed the detection of both the PCV E protein and WNV.sub.KUN NS1 protein, but not the expression of PCV NS1 or WNV.sub.KUN E proteins (FIG. 10), indicating that the correct chimeric virus was made. The authenticity of the WNV.sub.KUN/PCV-prME chimera was further verified by sequencing the viral RNA isolated from passaged P.sub.1 C6/36 supernatant.

Example 8. Chimeric ISF Vectors

(446) Guided by the results set forth in Example 7, preferred chimeric ISF vectors suitable for production using CPEC have been designed and tested, and also found to be capable of replicating virus:

(447) PCV/WNV.sub.KUN-prME (SEQ ID NO:11)

(448) PCV/ZIKA-prME (SEQ ID NO:12);

(449) PCV/DENV2-prME (SEQ ID NO:13);

(450) BgV/WNV.sub.KUN-prME (SEQ ID NO:14);

(451) BinJV/WNV.sub.KUN-prME (SEQ ID NO:388);

(452) BinJV/ZIKV-prME (SEQ ID NO:390);

(453) BinJV/DENV1-prME (SEQ ID NO:394);

(454) PaRV/KRBV-prM (SEQ ID NO:398)

(455) Primers used to produce a subset of the above vectors by CPEC are set forth in Table 1.

(456) These chimeric ISF vectors were designed to replicate chimeric ISFs comprising immunogenic sequences in the form of prME or prM proteins encoded by the genome of a flaviviruse that is not insect-specific; and C and NS1-NS5 proteins encoded by the genome of an insect-specific flavivirus that is capable of infecting a plurality of types of insect cells.

(457) By way of example, detail regarding the structural features of a subset of the above vectors is provided below. Similar information will be readily determinable for the remaining vectors by the skilled person, using standard bioinformatics tools in combination with the flavivirus sequences used for the chimeric ISF vectors, and the examples provided herein.

(458) PCV/WNV.sub.KUN-prME

(459) PCV/WNV.sub.KUN-prME vector is designed to replicate a chimeric ISF containing prME from WNV, and the remaining flavivirus proteins (C and NS1-NS5) from PCV. Nucleotide sequence of the vector is set forth in SEQ ID NO:11, with reference to FIG. 22. Key features of the vector are as follows:

(460) OpIE2-CA promoter: nucleotides 427-958

(461) 5′UTR from PCV: nucleotides 959-1056

(462) Region encoding C protein from PCV: nucleotides 1057-1464

(463) Region encoding prM protein from KUNV: nucleotides 1465-1965

(464) Region encoding E protein from KUNV: nucleotides 1966-3468

(465) Region encoding NS1 protein from PCV: nucleotides 3469-4624

(466) Region encoding NS2A protein from PCV: nucleotides 4625-5352

(467) Region encoding NS2B protein from PCV: nucleotides 5353-5733

(468) Region encoding NS3 protein from PCV: nucleotides 5734-7494

(469) Region encoding NS4A protein from PCV: nucleotides 7495-8010

(470) Region encoding NS4B protein from PCV: nucleotides 8011-8769

(471) Region encoding NS5 protein from PCV: nucleotides 8770-11436

(472) 3′UTR from PCV: nucleotides 11437-11978

(473) When transfected in C6/36 cells, this vector produced chimeric insect-specific flavivirus at a titre of 1.7×10.sup.6/ml.

(474) PCV/ZIKA-prME

(475) PCV/ZIKA-prME vector is designed to replicate a chimeric ISF containing prME from ZIKA, and the remaining flavivirus proteins (C and NS1-NS5) from PCV. Nucleotide sequence of the vector is set forth in SEQ ID NO:12, with reference to FIG. 23. Key features of the vector are as follows:

(476) OpIE2-CA promoter: nucleotides 427-958

(477) 5′UTR from PCV: nucleotides 959-1056

(478) Region encoding C protein from PCV: nucleotides 1057-1464

(479) Region encoding prM protein from ZIKA: nucleotides 1465-1968

(480) Region encoding E protein from ZIKA: nucleotides 1969-3480

(481) Region encoding NS1 protein from PCV: nucleotides 3481-4636

(482) Region encoding NS2A protein from PCV: nucleotides 4637-5364

(483) Region encoding NS2B protein from PCV: nucleotides 5365-5745

(484) Region encoding NS3 protein from PCV: nucleotides 5746-7506

(485) Region encoding NS4A protein from PCV: nucleotides 7507-8022

(486) Region encoding NS4B protein from PCV: nucleotides 8023-8781

(487) Region encoding NS5 protein from PCV: nucleotides 8782-11448

(488) 3′UTR from PCV: nucleotides 11449-11990

(489) When transfected in C6/36 cells, this vector produced chimeric insect specific flavivirus at a titre of 3.9×10.sup.7/ml.

(490) PCV/DENV2-prME

(491) PCV/DENV2-prME vector is designed to replicate a chimeric ISF containing prME from DENV2, and the remaining flavivirus proteins (C and NS1-NS5) from PCV. Nucleotide sequence of the vector is set forth in SEQ ID NO:13, with reference to FIG. 24. Key features of the vector are as follows:

(492) OpIE2-CA promoter: nucleotides 427-958

(493) 5′UTR from PCV: nucleotides 959-1056

(494) Region encoding C protein from PCV: nucleotides 1057-1464

(495) Region encoding prM protein from DENV2: nucleotides 1465-1962

(496) Region encoding E protein from DENV2: nucleotides 1963-3447

(497) Region encoding NS1 protein from PCV: nucleotides 3448-4603

(498) Region encoding NS2A protein from PCV: nucleotides 4604-5331

(499) Region encoding NS2B protein from PCV: nucleotides 5332-5712

(500) Region encoding NS3 protein from PCV: nucleotides 5713-7473

(501) Region encoding NS4A protein from PCV: nucleotides 7474-7989

(502) Region encoding NS4B protein from PCV: nucleotides 7990-8748

(503) Region encoding NS5 protein from PCV: nucleotides 8749-11415

(504) 3′UTR from PCV: nucleotides 11416-11957

(505) When transfected in C6/36 cells, this vector produced chimeric insect-specific flavivirus at a titre of 3.6×10.sup.5/ml.

(506) BgV/WNV.sub.KUN-prME

(507) BgV/WNV.sub.KUN-prME vector is designed to replicate a chimeric ISF containing prME from KUNV, and the remaining flavivirus proteins (C and NS1-NS5) from BgV. Nucleotide sequence of the vector is set forth in SEQ ID NO:14, with reference to FIG. 25. Key features of the vector are as follows:

(508) OpIE2-CA promoter: nucleotides 427-958

(509) 5′UTR from BgV: nucleotides 959-1074

(510) Region encoding C protein from BgV: nucleotides 1075-1416

(511) Region encoding prM protein from KUNV: nucleotides 1417-1917

(512) Region encoding E protein from KUNV: nucleotides 1918-3420

(513) Region encoding NS1 protein from BgV: nucleotides 3421-4476

(514) Region encoding NS2A protein from BgV: nucleotides 4477-5151

(515) Region encoding NS2B protein from BgV: nucleotides 5152-5541

(516) Region encoding NS3 protein from BgV: nucleotides 5542-7407

(517) Region encoding NS4A protein from BgV: nucleotides 7408-7785

(518) Region encoding 2K protein from BgV: nucleotides 7786-7854

(519) Region encoding NS4B protein from BgV: nucleotides 7855-8595

(520) Region encoding NS5 protein from BgV: nucleotides 8596-11310

(521) 3′UTR from PCV: nucleotides 11311-11830

(522) When transfected in C6/36 cells, this vector produced chimeric insect-specific flavivirus at a titre of 10.sup.815 infectious units/ml.

Example 9. Further Chimeric ISF Vectors

(523) The following further chimeric ISF vectors suitable for production using CPEC were designed:

(524) WNV.sub.KUN/BgV-prME (SEQ ID NO:23);

(525) WNV.sub.KUN/BinJV-prME (SEQ ID NO:25); and

(526) WNV.sub.KUN/KRBV-prME (SEQ ID NO:29).

(527) Primers used to produce the above vectors by CPEC are set forth in Table 1.

(528) These chimeric ISF vectors are designed to replicate chimeric ISFs comprising immunogenic sequences in the form of C and NS1-NS5 proteins encoded by the genome of a flaviviruse that is not insect-specific, and prME proteins encoded by the genome of an insect-specific flavivirus.

(529) The key regions of these respective vectors are similar as set forth in Example 8, and can readily be discerned by the skilled person, e.g. using suitable bioinformatics tools.

Example 10. Increasing the Specificity of Diagnostic Antigens Using ISF-VIF.SUB.EDIII .and ISF—VIF.SUB.prM .Chimeras

(530) Diagnosing flavivirus infection is notoriously difficult due to the cross-reactivity of antibodies to the conserved immuno-dominant antigenic epitopes in the fusion loop of domain II of the E protein. This is a substantial issue for serologically differentiating between ZIKV and DENY infections. However, it has been shown that the E protein domain III subunit (EDIII) can confer diagnostic specificity for differentiating antibody responses to closely related flaviviruses such as WNV, Murray Valley encephalitis virus (MVEV), JEV and St Louis encephalitis virus. Furthermore, recent analysis of the human antibody response to Zika or dengue revealed that 90% of EDIII-reactive antibodies are specific to the infecting virus making EDIII a prime candidate for Zika diagnostics. The flavivirus prM protein similarly confers diagnostic specificity and has been shown to differentiate between antibody responses to DENY and JEV and between WNV and MVEV.

(531) It has been recognised for this invention that chimeric insect-specific flaviviruses as described herein which feature particular immunogenic E protein domains and/or prM proteins may offer substantial advantages in regard to specificity of antibody binding. In particular, it is considered that chimeric insect-specific flaviviruses wherein the EDIII domain is of or derived from a vertebrate infecting flavivirus (VIF), and the remainder of the E protein is of or derived from an insect-specific flavivirus (see, e.g., FIG. 61), may be particularly desirable in regard to the specificity of responses of antibodies produced against the VIF.

(532) Notably, in experiments conducted for the invention, no cross-reactivity has been observed upon assessment of PCV, PaRV and BinJV proteins with extensive panels of mAbs specific to vertebrate E and prM proteins. This suggests that, where the immunogenic sequence of at least certain preferred isolated proteins or chimeric insect-specific flaviviruses as herein described is of or derived from a VIF that is highly specific for the VIF (e.g. the EDIII domain), the protein or chimeric insect-specific flaviviruses should show overall very high specificity in regard to binding of antibodies targeting the VIF.

(533) Systematic assessment of the use of PCV, PaRV and BinJV E protein scaffolds for the expression of the EDIII domain of the E protein or prM of WNV, DENY and ZIKV E domain- and prM-specific chimeras is therefore to be conducted. Specificity of binding of antibodies to these chimeric proteins of the invention will be assessed using panels of well-characterised immune serum to WNV, DENY or ZIKV from naturally infected humans and animals. To further challenge the specificity of the proteins, immune sera to heterologous flavivirus infections will similarly be assessed, including that from MVEV and JEV virus-infected individuals. Highly specific binding of WNV, DENY, or ZIKV antibodies to the respective isolated proteins is anticipated.

(534) An example of such an isolated protein (BinJV/WNV.sub.KUNv-EDIII) that is to be assessed, comprising BinJV C, NS1-NS5, and prM amino acid sequence, and chimeric E protein amino acid sequence wherein the EDIII domain is of WNV and the remaining amino acid sequence is of BinJV, is set forth in SEQ ID NO:32. A CPEC vector encoding the BinJV/WNV.sub.KUNV-EDIII protein is set forth in SEQ ID NO:33. Initial in silico analysis suggests that the BinJV E protein may be a particularly strong candidate for exchange of these regions with WNV, as has been performed in the BinJV/WNV.sub.KUNV-EDIII protein. This is due to the presence of few deletions within the BinJV E protein amino acid sequence as compared to VIF E proteins, and high overall homology with VIF E proteins.

(535) Isolated chimeric proteins such as BinJV/WNV.sub.KUNV-EDIII that are confirmed to be bound by corresponding antibodies with high specificity, using the approach set out in this example, will be considered particularly desirable for diagnostic applications as described herein.

Example 11. Lilly Creek Virus

(536) A new virus has been discovered for the purposes of this invention that is related to BinJV, but is a distinct species. The virus has been named ‘Lilly Creek virus’ (abbreviated herein as LiCV or LLCFV), and shares 90.8% amino acid identity and 76.3% nucleotide identity across the ORF with BinJV (FIG. 74). Phylogenetically, BinJV and LiCV branch together (FIG. 76). Accordingly, LiCV is considered a Lineage II ISF. The genomic sequence of LiCV is set forth in SEQ ID NO:386 (FIG. 62). The amino acid sequence of the ORF of LiCV is set forth in SEQ ID NO:387 (FIG. 63).

(537) It has been determined for the invention that LiCV displays an insect-specific phenotype substantially the same as BinJV, with no replication detected in vertebrate cells (FIG. 77).

(538) LiCV sequence is considered desirable for the purpose of producing chimeric ISF vectors similar to those herein described. It is noted that, despite overall high similarity, differences in the amino acid sequences between BinJV and LiCV may make one or the other better for chimerisation with VIFs, particularly for the production of envelope protein domain chimeras. As set out in FIG. 78, across the envelope protein, BinJV and LiCV display differences in homology with VIF envelope protein sequences.

Example 12. Growth Kinetics of BinJV and Associated ISF Chimeras

(539) A comparative assessment of growth of BinJV virus and associated chimeric ISF vectors (BinJV/WNV-prME; BinJV/ZIKV-prME, and BinJV/WNV-EDI) with PCV and an associated chimeric ISF vector (PCV/WNV.sub.KUN-prME) was performed. For this assessment, similar as hereinabove described C6/36 mosquito cell cultures were inoculated with the wild type ISF viruses or chimeric viruses and harvested 5-7 days post-infection. The infectious virus titre of the resulting stock was determined by titration onto mosquito cells.

(540) Results are set forth in FIG. 79. The growth of BinJV and associated chimeras was higher than PCV and associated chimeras. It will be appreciated that, in some circumstances BinJV chimeric ISF constructs may be especially preferred for optimal or greater yield of virus particles, although without limitation thereto.

Example 13. Host Restriction Analysis of BinJV

(541) An assessment of the ability of BinJV to infect and replicate in various vertebrate cell lines (including those with defective interferon response: MEF IFNAR.sup.−/−), and mosquito cell lines (including those of Culex, Aedes and Anopheles origin) was undertaken. The results are set forth in FIG. 80, and demonstrate that BinJV cannot infect or replicate in vertebrate cells to any substantial extent, but can successfully infect and replicate in a range of mosquito cells.

(542) In view of this data, use of BinJV for chimeric ISF vectors as described herein may be particularly desirable in at least some circumstances, e.g. from a safety perspective such as in the context of diagnostics and/or vaccines, and/or from a flexibility perspective with respect to suitable insect cells for use in replication of the chimeric ISFs.

Example 14. Host Restriction Analysis of Chimeric ISF at Lowered Temperature

(543) In certain cases, viral replication can be restricted in a particular cell at 37° C., but replication can occur at lower temperatures (e.g. 34° C.). To explore this in the context of the chimeric ISFs described herein, assessment of an exemplary chimeric ISF (BinJV/WNV.sub.KUN-prME) was performed at 37° C. and 34° C. in a range of mammalian cell lines. Wild type BinJV and WNV.sub.KUN virus was included as a control, as were mosquito cells (RNAi-deficient C6/36 Aedes cells).

(544) Results are set forth in FIG. 81. It will be evident from these results that the exemplary chimeric ISF assessed cannot replicate in mammalian cells, even under conditions of lowered temperature. This indicates that chimeric ISFs as described herein may be particularly desirable from a safety perspective, e.g. in the context of use as diagnostics and/or vaccines.

Example 15. Mutation of EDII Fusion Loop

(545) BinJV and LiCV lack an immunodominant residue in its EDII fusion loop (G106V). Only two other linage II ISFs discovered to date similarly lack this residue. The significance of this is that this change in residue results in significantly less cross-reactivity for diagnostic applications. A number of monoclonal antibodies specific to the G106 phenotype are available, of which mAb 4G2 is an example. Due to the G106V substitution that naturally occurs in BinJV, mAb 4G2 does not bind. For the purposes of this invention the BinJV EDII fusion loop has been successfully manipulated to G106 to prove that manipulation of this region is possible, e.g. in other ISFs. IFA analysis using anti-flavivirus NS1 mAb 4G4 and anti-flavivirus E mAb 4G2 was then performed. Results are set forth in FIG. 83.

Example 16. Domain I Chimeras

(546) It has previously been shown that a 19 amino acid peptide in domain I of West Nile virus E protein can be used for diagnostic applications (Hobson-Peters et al., 2008, J Gen Virol). However, this 19 amino acid peptide is not typically present in ISF E proteins. For the purposes of this invention, domain I of BinJV has been mutated to express this 19 amino acid peptide. The presence of the domain I peptide was confirmed by binding of a specific antibody, and the BinJV/WNV.sub.EDI chimera replicated to high titres (>10.sup.8/ml), as set forth in FIG. 84. This confirms that E protein domains can be exchanged between vertebrate infecting flaviviruses and ISFs.

Example 17. PCV-Based Chimeric ISFs

(547) As herein described, various chimeric ISF including PCV sequence and sequence from vertebrate-infecting flaviruses (VIFs) have been produced. Replication of PCV/WNV.sub.KUN-prME, pCV/DENV-prME, and PCV/ZIKV-prME in mosquito cells, and comparison with replication of the corresponding wild type ISF and VSF has been assessed. Results are presented in FIG. 85.

Example 18. Effect of Passaging on Chimeric ISFs

(548) The effect of serially passaging chimeric ISFs as described herein through mosquito cells has been assessed. Specifically, PCV/ZIKV-prME and PCV/WNV.sub.KUN-prME were passaged serially blind through C6/36 cells. Chimeric ISFs exposed to one passage (P1) (SEQ ID NO:400) and ten passages (P10) (SEQ ID NO:401) were then sequenced and compared Additionally, the growth kinetics of replication of wild type PCV, and P1 and P10 chimeric ISFs in C6/36 cells was compared (FIG. 86)

(549) Based on sequence comparison, the P10 of PCV/ZIKV-prME featured certain genetic changes compared to the P1 of this chimera. Furthermore, replication of the P10 chimeric ISFs was found to be elevated, relative to the P1 ISFs. Without being bound by theory it is considered that genetic changes that occurred during serial passaging resulted in optimisation of replication of the chimeric ISFs in insect cells.

Example 19. Antigenic Authenticity of Chimeric ISFs

(550) For this example, PCV/WNV.sub.KUN-prME, BinJV/WNV.sub.KUN-prME, PCV/ZIKV-prME and BinJV/ZIKV-prME chimeras were presented either as purified virions coated onto microwell plates, or as fixed antigens in infected C6/36 mosquito cell monolayers. The antigens were probed with monoclonal antibodies specific to individual domains of WNV or ZIKV envelope protein (EDI, EDII, EDIII), prM or quaternary structures of prM and E. The successful binding of these mAbs to the chimeric viruses confirmed their antigenic authenticity. The absence of WNV and ZIKV NS1 (which is not part of the chimeric constructs) was confirmed by assessing with NS1-specific mAbs. Results are set forth in Tables 2 and 3.

Example 20. Recognition of Chimeric ISFs by Human and Animal Sera

(551) Utility of ISF chimeric viral antigens in diagnostic assays was assessed by study of the binding of immune human, horse and crocodile sera to chimeric ISFs in fixed cell ELISA using virus-infected C6/36 mosquito cell monolayers. Specifically, binding WNV-immune sera to PCV/WNV.sub.KUN-prME was assessed. As controls, negative human sera and virus-specific monoclonal antibodies were included, as well as wild type PCV and WNV. As set forth in FIG. 87, there was negligible reactivity of naïve sera. In contrast, substantial reactivity of WNV-immune sera with PCV/WNV.sub.KUN-prME and wild type WNV occurred. Control reactions were essentially as expected.

(552) Similarly, binding of PCV/ZIKV-prME with ZIKV-immune human sera was assessed in ELISA, as set forth in FIG. 88. Purified PCV/ZIKV-prME virions were coated onto 96-well ELISA microwell plates and probed with human serum at a dilution of 1/320. Bound human antibodies were detected with a HRP-conjugated anti-human Ig. The OD of similarly diluted serum on mock-coated wells was subtracted. The ZIKV positive human serum bound PCV/ZIKV-prME virions strongly, while there was negligible reactivity of a ZIKV-naïve serum.

Example 21. Assessment of Cross-Reactivity of BinJV E Proteins in Chimeric ISFs

(553) As set forth in FIG. 93, lysates of BinJV or KUNV-infected cells were coated onto ELISA plates at a pre-determined dilution (1/1000) giving the maximum level of E protein binding for both viruses. Comparable amounts of viral antigen were confirmed by the similar binding of anti-NS1 mAb 4G4 and anti-E mAb (4G2 for KUNV and 3A3 for BinJV). WNV-immune horse sera clearly reacted to KUNV lysate (blue bars), while there was negligible reactivity of these sera to BinJV. WNV positive horse sera (experimentally infected with WNV)=JPA8, 46, 12, 17, 32. WNV-naïve horse sera=neg 1, neg 2. Binding of sera to mock lysate subtracted from all readings. These results demonstrate that BinJV E proteins have minimal cross-reactivity when probed with immune sera, indicating that they may make ideal scaffolds for the preparation of E subdomain chimeras.

Example 22. Chimeric ISFs as Vaccines

(554) As set forth in FIG. 89, WNV-immune human, horse, crocodile, and rabbit sera neutralizes PCV/WNV.sub.KUN-prME and BinJV/WNV.sub.KUN-prME with similar efficiency to WNV. Similar findings were observed for PCV/ZIKV-prME as compared with ZIKV (FIG. 90). This is strong evidence that insect specific flavivirus (ISF)/vertebrate infecting flavivirus (VIF) chimeras are antigenically authentic and can induce robust VIF-neutralising responses.

(555) It has also been demonstrated that immunization of mice with purified BinJV particles (2 doses of 10-20 ug of purified particle+Advax) induces a potent neutralising response (titre of 640). This strategy should also be effective using chimeric ISF particles.

Example 23. Codon Optimisation

(556) Insects and mammals have evolved different protein encoding strategies (codon pair bias). There is evidence that ISFs have optimised their codon pair bias to be more similar to that of insects (Colmant et al. (2017) mSphere 2(4) pii: e00262-17). In contrast, it appears that VIFs like WNV, ZIKV, and DENY ‘balance’ their codon optimisation between insects and mammals Codon optimisation of the VIF prME sequences that have been inserted into chimeric ISF vectors as described herein will be optimised to an insect-like codon pair bias, with the intention of enabling the chimeric ISFs to replicate more efficiently in insect cells, and/or supress their replication in vertebrate cells. As proof of concept for this approach, when the genomes of dengue viruses were recoded to an insect-like codon pair bias, they grew well in insect cells but became highly attenuated in mammalian cells (Shen et al., 2015, PNAS, 112; 4749-4754). Thus, the proposed codon optimisation approach may provide an additional safety mechanism for chimeric ISF applications, and/or improve growth in mosquito cell cultures for scale-up production purposes.

Example 24. Restriction of Unwanted Replication Using miRNA

(557) It has been realised for the invention that it may be possible to provide a further safety measure for use of chimeric ISFs as described herein, e.g., in the context of use as vaccine for vertebrate viruses, using an small RNA (e.g. miRNA)-based approach. Specifically, with reference to Teterina et al., 2014, Virology, 456; 247-258 and Zhou et al., 2014, Parasites & Vectors, 7; 488, it is possible to modulate replication of flaviviruses in specific cells or tissues by incorporating target sequence of regulatory miRNA into the flavivirus sequence.

(558) Accordingly, an approach will be explored wherein target miRNA sequence is incorporated into chimeric ISFs as described herein, to constrain or prevent replication of the chimeric ISF in the mosquito midgut. It will be appreciated that, in the unlikely event that a chimeric ISF was transferred from a vertebrate subject (e.g. after vaccination with the chimeric ISF) to a mosquito by feeding by the mosquito on the subject, the inclusion of such an miRNA target sequence could prevent or constrain replication of the chimeric ISF in the mosquito.

(559) Throughout the specification, the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one embodiment or specific collection of features. Various changes and modifications may be made to the embodiments described and illustrated without departing from the present invention.

(560) The disclosure of each patent and scientific document, computer program and algorithm referred to in this specification is incorporated by reference in its entirety.

Tables

(561) TABLE-US-00001 TABLE 1 Primers used for CPEC amplification to produce chimeric insect-specific flavivirus vectors. SEQ  Sequence Name Name Direction Sequence ID NO BgV/WNV-prME [CA] BgV10722R reverse GATTCTTGTCGTTTCTCG 48 BgV/WNV-prME [CA] BgV10613F forward CACACACGGATCACATTGACACC 49 BgV/WNV-prME [CA] BgNS5_R reverse GTGCTTTAATTTATATCAAG 50 BgV/WNV-prME [CA] Bg3′UTR_F forward CTTGATATAAATTAAAGCAC 51 BgV/WNV-prME [CA] BgNS5-30_R reverse GGTTGGTTTAATGGAGTGCTTTAATTTATATCAAGCAGCC 52 AATTTCGGAGTGTTCC BgV/WNV-prME [CA] BgV9649F forward GCTCCCACCATTTCCACCATTTGC 53 BgV/WNV-prME [CA] BgNS4B_R reverse CTCACCACCTCCTCTTTTGGG 54 BgV/WNV-prME [CA] BgNS5_F forward CCCAAAAGAGGAGGTGGTGAG 55 BgV/WNV-prME [CA] BgNS4B-30_R reverse GCCAAGGGTCATGGTCTCACCACCTCCTCTTTTGGGGTTT 56 TGCAATATCC BgV/WNV-prME [CA] BgNS5-30_F forward GGATATTGCAAAACCCCAAAAGAGGAGGTGGTGAGACCA 57 TGACCCTTGGC BgV/WNV-prME [CA] BgNS2B_R reverse CAAAACTCCACTGCGCTGGC 58 BgV/WNV-prME [CA] BgNS3_F forward GCCAGCGCAGTGGAGTTTTG 59 BgV/WNV-prME [CA] BgVNS2B-30_R reverse GGCACGTCCCACAAAACTCCACTGCGCTGGCTTTTGCCTG 60 C BgV/WNV-prME [CA] BgNS2B-30_R reverse GGCACGTCCCACAAAACTCCACTGCGCTGGCTTTTGCCTG 61 C BgV/WNV-prME [CA] BgVNS3-30_F forward GCAGGCAAAAGCCAGCGCAGTGGAGTTTTGTGGGACGTG 62 CC BgV/WNV-prME [CA] BgV-NS2A_F forward GGTGACGGGATGGAAAATGG 63 BgV/WNV-prME [CA] BgV-NS1_R reverse GGCACTTACCCATGAAGTGACC 64 BgV/WNV-prME [CA] KE/BNS1_R reverse GAGCAACCGTACTCAGCATGCACGTTCACGG 65 BgV/WNV-prME [CA] KE/BNS1_F forward CCGTGAACGTGCATGCTGAGTACGGTTGCTC 66 BgV/WNV-prME [CA] KUN-E-Seq-F forward GCATGGACCAACTACCG 67 BgV/WNV-prME [CA] KUNV-C-prM_R reverse GGAAATCTCTGTTGCTCATTCCAAGACAG 68 BgV/WNV-prME [CA] KUNV-E_F forward CTGTCTTGGAATGAGCAACAGAGATTTCC 69 BgV/WNV-prME [CA] BC/KPr_F forward GCAACAACATGGGCCGTCACTCTCTCCAAC 70 BgV/WNV-prME [CA] BgV-92F forward GCACACTAGTTTGTGACATAAGGC 71 BgV/WNV-prME [CA] BgV-103F forward CGCTTGTTTTGGCACACTAG 72 BgV/WNV-prME [CA] BgV10739R reverse GCGTACGGATTTTACG 73 BgV/WNV-prME [CA] BgV-116Fs forward CGTAAAATCCGTACGC 74 BgV/WNV-prME [CA] BgV-5UTR-CA-2R reverse GTACGGATTTTACGGTTTACCAGATCG 75 BgV/WNV-prME [CA] BgV-5UTR-CA-2F forward CGATCTGGTAAACCGTAAAATCCGTAC 76 BgV/WNV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 77 BgV/WNV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 78 BgV/WNV-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 79 BinJV/WNV-EDIII [CA] BinJV_NS5-3′_R reverse TGCCATGCCGACCCAGATACTTGATGTTTC 80 BinJV/WNV-EDIII [CA] BinJV3′UTR- reverse TGCCATGCCGACCCAGATACTTGATGTTTC 81 linker BinJV/WNV-EDIII [CA] BinJV_NS5- forward GGCAATGTGATCTAAGGATCTACGAACGAG 82 3′Junc_F BinJV/WNV-EDIII [CA] BinJV_NS5- reverse CTCGTTCGTAGATCCTTAGATCACATTGCC 83 3′Junc_R BinJV/WNV-EDIII [CA] BinJV_NS5-3′_F forward GGAGTTCCTAGGAGGGGATTACAGGCCACC 84 BinJV/WNV-EDIII [CA] BinJV_3-4B_R reverse GGTGGCCTGTAATCCCCTCCTAGGAACTCC 85 BinJV/WNV-EDIII [CA] BinJV_3-4B_F forward AAATCAAACAAGCGGGGGACTGTGTTGTGG 86 BinJV/WNV-EDIII [CA] BinJV_1-2B_R reverse CCACAACACAGTCCCCCGCTTGTTTGATTT 87 BinJV/WNV-EDIII [CA] BinJV_1-2B_F forward GTGACCGTGGGTGCCCTATCGGAAATAGGA 88 BinJV/WNV-EDIII [CA] BinJV_5′-E_R reverse TCCTATTTCCGATAGGGCACCCACGGTCAC 89 BinJV/WNV-EDIII [CA] BinJV-E_F forward GCTCCGTCATATGGTAACCAATGCCTGGAT 90 BinJV/WNV-EDIII [CA] BinJV-M_R reverse ATCCAGGCATTGGTTACCATATGACGGAGC 91 BinJV/WNV-EDIII [CA] BinJV_5′-E_F forward AACGATCTGGTAAACAGTATATTTTGCGTG 92 BinJV/WNV-EDIII [CA] Linker- reverse CACGCAAAATATACTGTTTACCAGATCGTT 93 BinJV5′UTR BinJV/WNV-EDIII [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 94 BinJV/WNV-EDIII [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 95 BinJV/WNV-EDIII [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 96 WNV/BgV-prME [CA] KUNV-3′UTR_R reverse TCCTGTGTTCTCGCACCAC 97 WNV/BgV-prME [CA] KUNV-UTRlinker_F forward GTGGTGCGAGAACACAGGA 98 WNV/BgV-prME [CA] KUN-NS5(only)-R reverse TTACAATACTGTATCCTCAACCAATG 99 WNV/BgV-prME [CA] KUNV-NS5_R reverse CTGTATCCTCAACCAATGTTGTGTCTTC 100 WNV/BgV-prME [CA] KUNV-3′UTR_F forward GAAGACACAACATTGGTTGAGGATACAG 101 WNV/BgV-prME [CA] KUN-NS5(only)-F forward GGTGGGGCAAAAGGAC 102 WNV/BgV-prME [CA] KUNV-NS4B_R reverse CGTCCTTTTGCCCCACCTC 103 WNV/BgV-prME [CA] KUNV-NS5_F forward GAGGTGGGGCAAAAGGACG 104 WNV/BgV-prME [CA] KUNV-NS4A_R reverse CCCATCTCATTGGCTGCCAC 105 WNV/BgV-prME [CA] KUNV-NS4B_F forward GTGGCAGCCAATGAGATGGG 106 WNV/BgV-prME [CA] qWNns4A R reverse TAGCTGGTTGTCTGTCTGCG 107 WNV/BgV-prME [CA] qWNns4A F forward TTGAGTGTGATGACCATGGGAG 108 WNV/BgV-prME [CA] KUNV-NS3_R reverse GACCTCGATAAAACCTATTTGAGAGCGC 109 WNV/BgV-prME [CA] KUNV-NS4A_F forward GCGCTCTCAAATAGGTTTTATCGAGGTC 110 WNV/BgV-prME [CA] KUNV-NS2B_R reverse CTCCTCTCTTTGTGTATTGGAGAGTTATC 111 WNV/BgV-prME [CA] KUNV-NS3_F forward GATAACTCTCCAATACACAAAGAGAGGAG 112 WNV/BgV-prME [CA] KUNV-NS2A_R reverse CTTCAGTTGCAGGCCACCC 113 WNV/BgV-prME [CA] KUNV-NS2B_F forward GGGTGGCCTGCAACTGAAG 114 WNV/BgV-prME [CA] KUNV-NS1_R reverse GAAAAGGATCAATCATGTCAGCGTTGTAG 115 WNV/BgV-prME [CA] KUNV-NS2A_F forward CTACAACGCTGACATGATTGATCCTTTTC 116 WNV/BgV-prME [CA] KUN-NS1-INT_R reverse CGGTCCATCCAAGCTTCCAC 117 WNV/BgV-prME [CA] BE/KNS1-15_R reverse GGCACATCCAGTATCAGCGTTAACTCCAAG 118 WNV/BgV-prME [CA] BE/KNS1-15_F forward CTTGGAGTTAACGCTGATACTGGATGTGCC 119 WNV/BgV-prME [CA] BE/KNS1_R reverse CCGACTTATATCTATGGCACATCCAGTATCAGCGTTAACT 120 CCAAGTGTCATGAACAACAG WNV/BgV-prME [CA] BE/KNS1_F forward CTGTTGTTCATGACACTTGGAGTTAACGCTGATACTGGAT 121 GTGCCATAGATATAAGTCGG WNV/BgV-prME [CA] K/B(S)-E-SEQ_F forward GATAGGTGTGAACTCCCGCAATG 122 WNV/BgV-prME [CA] BgVE_F forward CCTGCTTACGGCTCTCACTGCATTG 123 WNV/BgV-prME [CA] BgV-PrM_R forward GGCAATTGGACCTGCTTACG 124 WNV/BgV-prME [CA] BgV531R reverse GCAATCAATGTCGTCAGGCTCTTCC 125 WNV/BgV-prME [CA] K/B(S)-Pr-SEQ_R reverse CACCAGTATCCAGCATCATTGATG 126 WNV/BgV-prME [CA] KC/BPr-15_R reverse CTTCCTGAGAGTTAATGCTCCCACGCCAG 127 WNV/BgV-prME [CA] KC/BPr-15_F forward CTGGCGTGGGAGCATTAACTCTCAGGAAG 128 WNV/BgV-prME [CA] KC/BPr_R reverse AATAGTGTTGTCAATCTTCCTGAGAGTTAATGCTCCCACG 129 CCAGCAATCAAGCCAATCAT WNV/BgV-prME [CA] KC/BPr_F forward ATGATTGGCTTGATTGCTGGCGTGGGAGCATTAACTCTCA 130 GGAAGATTGACAACACTATT WNV/BgV-prME [CA] K/B(S)-C-SEQ_F forward CAGAAGAAGAGAGGAGGAAAGACC 131 WNV/BgV-prME [CA] KUNV-5′UTR_R reverse GGCCCTCCTGGTTTCTTAGAC 132 WNV/BgV-prME [CA] KUNV-C-prM_F forward GTCTAAGAAACCAGGAGGGCC 133 WNV/BgV-prME [CA] KUNV-UTRlinker_R reverse CAGCTCACACAGGCGAACTACT 134 WNV/BgV-prME [CA] KUNV-5′UTR_F forward AGTAGTTCGCCTGTGTGAGCTG 135 WNV/BgV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 136 WNV/BgV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 137 WNV/BgV-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 138 WNV/BinJV-prME [CA] KUNV-3′UTR_R reverse TCCTGTGTTCTCGCACCAC 139 WNV/BinJV-prME [CA] KUNV-UTRlinker_F forward GTGGTGCGAGAACACAGGA 140 WNV/BinJV-prME [CA] KUN-NS5(only)-R reverse TTACAATACTGTATCCTCAACCAATG 141 WNV/BinJV-prME [CA] KUNV-NS5_R reverse CTGTATCCTCAACCAATGTTGTGTCTTC 142 WNV/BinJV-prME [CA] KUNV-3′UTR_F forward GAAGACACAACATTGGTTGAGGATACAG 143 WNV/BinJV-prME [CA] KUN-NS5(only)-F forward GGTGGGGCAAAAGGAC 144 WNV/BinJV-prME [CA] KUNV-NS4B_R reverse CGTCCTTTTGCCCCACCTC 145 WNV/BinJV-prME [CA] KUNV-NS5_F forward GAGGTGGGGCAAAAGGACG 146 WNV/BinJV-prME [CA] KUNV-NS4A_R reverse CCCATCTCATTGGCTGCCAC 147 WNV/BinJV-prME [CA] KUNV-NS4B_F forward GTGGCAGCCAATGAGATGGG 148 WNV/BinJV-prME [CA] qWNns4A R reverse TAGCTGGTTGTCTGTCTGCG 149 WNV/BinJV-prME [CA] qWNns4A F forward TTGAGTGTGATGACCATGGGAG 150 WNV/BinJV-prME [CA] KUNV-NS3_R reverse GACCTCGATAAAACCTATTTGAGAGCGC 151 WNV/BinJV-prME [CA] KUNV-NS4A_F forward GCGCTCTCAAATAGGTTTTATCGAGGTC 152 WNV/BinJV-prME [CA] KUNV-NS2B_R reverse CTCCTCTCTTTGTGTATTGGAGAGTTATC 153 WNV/BinJV-prME [CA] KUNV-NS3_F forward GATAACTCTCCAATACACAAAGAGAGGAG 154 WNV/BinJV-prME [CA] KUNV-NS2A_R reverse CTTCAGTTGCAGGCCACCC 155 WNV/BinJV-prME [CA] KUNV-NS2B_F forward GGGTGGCCTGCAACTGAAG 156 WNV/BinJV-prME [CA] KUNV-NS1_R reverse GAAAAGGATCAATCATGTCAGCGTTGTAG 157 WNV/BinJV-prME [CA] KUNV-NS2A_F forward CTACAACGCTGACATGATTGATCCTTTTC 158 WNV/BinJV-prME [CA] KUN-NS1-INT_R reverse CGGTCCATCCAAGCTTCCAC 159 WNV/BinJV-prME [CA] BinE-KUN1R reverse GGCACATCCAGTATCGGCACCCACGGTCAC 160 WNV/BinJV-prME [CA] BinE-KUN1F forward GTGACCGTGGGTGCCGATACTGGATGTGCC 161 WNV/BinJV-prME [CA] BinJV-M_R reverse ATCCAGGCATTGGTTACCATATGACGGAGC 162 WNV/BinJV-prME [CA] BinJV-E_F forward GCTCCGTCATATGGTAACCAATGCCTGGAT 163 WNV/BinJV-prME [CA] KUNC-BinprR reverse GGCTATCGTGATTGCTGCTCCCACGCCAGC 164 WNV/BinJV-prME [CA] KUNC-BinprF forward GCTGGCGTGGGAGCAGCAATCACGATAGCC 165 WNV/BinJV-prME [CA] K/B(S)-C-SEQ_F forward CAGAAGAAGAGAGGAGGAAAGACC 166 WNV/BinJV-prME [CA] KUNV-5′UTR_R reverse GGCCCTCCTGGTTTCTTAGAC 167 WNV/BinJV-prME [CA] KUNV-C-prM_F forward GTCTAAGAAACCAGGAGGGCC 168 WNV/BinJV-prME [CA] KUNV-UTRlinker_R reverse CAGCTCACACAGGCGAACTACT 169 WNV/BinJV-prME [CA] KUNV-5′UTR_F forward AGTAGTTCGCCTGTGTGAGCTG 170 WNV/BinJV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 171 WNV/BinJV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 172 WNV/BinJV-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 173 WNV/CFAV-prME [CA] KUNV-3′UTR_R reverse TCCTGTGTTCTCGCACCAC 174 WNV/CFAV-prME [CA] KUNV-UTRlinker_F forward GTGGTGCGAGAACACAGGA 175 WNV/CFAV-prME [CA] KUN-NS5(only)-R reverse TTACAATACTGTATCCTCAACCAATG 176 WNV/CFAV-prME [CA] KUNV-NS5_R reverse CTGTATCCTCAACCAATGTTGTGTCTTC 177 WNV/CFAV-prME [CA] KUNV-3′UTR_F forward GAAGACACAACATTGGTTGAGGATACAG 178 WNV/CFAV-prME [CA] KUN-NS5(only)-F forward GGTGGGGCAAAAGGAC 179 WNV/CFAV-prME [CA] KUNV-NS4B_R reverse CGTCCTTTTGCCCCACCTC 180 WNV/CFAV-prME [CA] KUNV-NS5_F forward GAGGTGGGGCAAAAGGACG 181 WNV/CFAV-prME [CA] KUNV-NS4A_R reverse CCCATCTCATTGGCTGCCAC 182 WNV/CFAV-prME [CA] KUNV-NS4B_F forward GTGGCAGCCAATGAGATGGG 183 WNV/CFAV-prME [CA] qWNns4A R reverse TAGCTGGTTGTCTGTCTGCG 184 WNV/CFAV-prME [CA] qWNns4A F forward TTGAGTGTGATGACCATGGGAG 185 WNV/CFAV-prME [CA] KUNV-NS3_R reverse GACCTCGATAAAACCTATTTGAGAGCGC 186 WNV/CFAV-prME [CA] KUNV-NS4A_F forward GCGCTCTCAAATAGGTTTTATCGAGGTC 187 WNV/CFAV-prME [CA] KUNV-NS2B_R reverse CTCCTCTCTTTGTGTATTGGAGAGTTATC 188 WNV/CFAV-prME [CA] KUNV-NS3_F forward GATAACTCTCCAATACACAAAGAGAGGAG 189 WNV/CFAV-prME [CA] KUNV-NS2A_R reverse CTTCAGTTGCAGGCCACCC 190 WNV/CFAV-prME [CA] KUNV-NS2B_F forward GGGTGGCCTGCAACTGAAG 191 WNV/CFAV-prME [CA] KUNV-NS1_R reverse GAAAAGGATCAATCATGTCAGCGTTGTAG 192 WNV/CFAV-prME [CA] KUNV-NS2A_F forward CTACAACGCTGACATGATTGATCCTTTTC 193 WNV/CFAV-prME [CA] KUN-NS1-INT_R reverse CGGTCCATCCAAGCTTCCAC 194 WNV/CFAV-prME [CA] CFAV-E/KUN-NS1_R reverse GGCACATCCAGTATCAGCCCGCACATAGTA 195 WNV/CFAV-prME [CA] CFAV-E/KUN-NS1_F forward TACTATGTGCGGGCTGATACTGGATGTGCC 196 WNV/CFAV-prME [CA] CFAV-Pr_R reverse AAACTCCCCCTTTACTGTGGTCCAAGTGCC 197 WNV/CFAV-prME [CA] CFAV-E_F forward GGCACTTGGACCACAGTAAAGGGGGAGTTT 198 WNV/CFAV-prME [CA] KUN-C/CFAV-Pr_R  reverse CATGTCAATCACCACTGCTCCCACGCCAGC 199 WNV/CFAV-prME [CA] KUN-C/CFAV-Pr_F forward GCTGGCGTGGGAGCAGTGGTGATTGACATG 200 WNV/CFAV-prME [CA] K/B(S)-C-SEQ_F forward CAGAAGAAGAGAGGAGGAAAGACC 201 WNV/CFAV-prME [CA] KUNV-5′UTR_R reverse GGCCCTCCTGGTTTCTTAGAC 202 WNV/CFAV-prME [CA] KUNV-C-prM_F forward GTCTAAGAAACCAGGAGGGCC 203 WNV/CFAV-prME [CA] KUNV-UTRlinker_R reverse CAGCTCACACAGGCGAACTACT 204 WNV/CFAV-prME [CA] KUNV-5′UTR_F forward AGTAGTTCGCCTGTGTGAGCTG 205 WNV/CFAV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 206 WNV/CFAV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 207 WNV/CFAV-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 208 WNV/KRBV-prME [CA] KUNV-3′UTR_R reverse TCCTGTGTTCTCGCACCAC 209 WNV/KRBV-prME [CA] KUNV-UTRlinker_F forward GTGGTGCGAGAACACAGGA 210 WNV/KRBV-prME [CA] KUN-NS5(only)-R reverse TTACAATACTGTATCCTCAACCAATG 211 WNV/KRBV-prME [CA] KUNV-NS5_R reverse CTGTATCCTCAACCAATGTTGTGTCTTC 212 WNV/KRBV-prME [CA] KUNV-3′UTR_F forward GAAGACACAACATTGGTTGAGGATACAG 213 WNV/KRBV-prME [CA] KUN-NS5(only)-F forward GGTGGGGCAAAAGGAC 214 WNV/KRBV-prME [CA] KUNV-NS4B_R reverse CGTCCTTTTGCCCCACCTC 215 WNV/KRBV-prME [CA] KUNV-NS5_F forward GAGGTGGGGCAAAAGGACG 216 WNV/KRBV-prME [CA] KUNV-NS4A_R reverse CCCATCTCATTGGCTGCCAC 217 WNV/KRBV-prME [CA] KUNV-NS4B_F forward GTGGCAGCCAATGAGATGGG 218 WNV/KRBV-prME [CA] qWNns4A R reverse TAGCTGGTTGTCTGTCTGCG 219 WNV/KRBV-prME [CA] qWNns4A F forward TTGAGTGTGATGACCATGGGAG 220 WNV/KRBV-prME [CA] KUNV-NS3_R reverse GACCTCGATAAAACCTATTTGAGAGCGC 221 WNV/KRBV-prME [CA] KUNV-NS4A_F forward GCGCTCTCAAATAGGTTTTATCGAGGTC 222 WNV/KRBV-prME [CA] KUNV-NS2B_R reverse CTCCTCTCTTTGTGTATTGGAGAGTTATC 223 WNV/KRBV-prME [CA] KUNV-NS3_F forward GATAACTCTCCAATACACAAAGAGAGGAG 224 WNV/KRBV-prME [CA] KUNV-NS2A_R reverse CTTCAGTTGCAGGCCACCC 225 WNV/KRBV-prME [CA] KUNV-NS2B_F forward GGGTGGCCTGCAACTGAAG 226 WNV/KRBV-prME [CA] KUNV-NS1_R reverse GAAAAGGATCAATCATGTCAGCGTTGTAG 227 WNV/KRBV-prME [CA] KUNV-NS2A_F forward CTACAACGCTGACATGATTGATCCTTTTC 228 WNV/KRBV-prME [CA] KUN-NS1-INT_R reverse CGGTCCATCCAAGCTTCCAC 229 WNV/KRBV-prME [CA] Kr-E/Ku-NS1_R reverse GGCACATCCAGTATCAGCTCGCACGTATGT 230 WNV/KRBV-prME [CA] Kr-E/Ku-NS1_F forward ACATACGTGCGAGCTGATACTGGATGTGCC 231 WNV/KRBV-prME [CA] Ku-C/Kr-E_R reverse TCCATTCATGGTCTTTGCTCCCACGCCAGC 232 WNV/KRBV-prME [CA] Ku-C/Kr-E_F forward GCTGGCGTGGGAGCAAAGACCATGAATGGA 233 WNV/KRBV-prME [CA] K/B(S)-C-SEQ_F forward CAGAAGAAGAGAGGAGGAAAGACC 234 WNV/KRBV-prME [CA] KUNV-5′UTR_R reverse GGCCCTCCTGGTTTCTTAGAC 235 WNV/KRBV-prME [CA] KUNV-C-prM_F forward GTCTAAGAAACCAGGAGGGCC 236 WNV/KRBV-prME [CA] KUNV-UTRlinker_R reverse CAGCTCACACAGGCGAACTACT 237 WNV/KRBV-prME [CA] KUNV-5′UTR_F forward AGTAGTTCGCCTGTGTGAGCTG 238 WNV/KRBV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 239 WNV/KRBV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 240 WNV/KRBV-prME [CA] DNA Linker - F forward GGGTCGGCATGGCATCTCC 241 WNV/PaRV-prME [CA] KUNV-3′UTR_R reverse TCCTGTGTTCTCGCACCAC 242 WNV/PaRV-prME [CA] KUNV-UTRlinker_F forward GTGGTGCGAGAACACAGGA 243 WNV/PaRV-prME [CA] KUN-NS5(only)-R reverse TTACAATACTGTATCCTCAACCAATG 244 WNV/PaRV-prME [CA] KUNV-NS5_R reverse CTGTATCCTCAACCAATGTTGTGTCTTC 245 WNV/PaRV-prME [CA] KUNV-3′UTR_F forward GAAGACACAACATTGGTTGAGGATACAG 246 WNV/PaRV-prME [CA] KUN-NS5(only)-F forward GGTGGGGCAAAAGGAC 247 WNV/PaRV-prME [CA] KUNV-NS4B_R reverse CGTCCTTTTGCCCCACCTC 248 WNV/PaRV-prME [CA] KUNV-NS5_F forward GAGGTGGGGCAAAAGGACG 249 WNV/PaRV-prME [CA] KUNV-NS4A_R reverse CCCATCTCATTGGCTGCCAC 250 WNV/PaRV-prME [CA] KUNV-NS4B_F forward GTGGCAGCCAATGAGATGGG 251 WNV/PaRV-prME [CA] qWNns4A R reverse TAGCTGGTTGTCTGTCTGCG 252 WNV/PaRV-prME [CA] qWNns4A F forward TTGAGTGTGATGACCATGGGAG 253 WNV/PaRV-prME [CA] KUNV-NS3_R reverse GACCTCGATAAAACCTATTTGAGAGCGC 254 WNV/PaRV-prME [CA] KUNV-NS4A_F forward GCGCTCTCAAATAGGTTTTATCGAGGTC 255 WNV/PaRV-prME [CA] KUNV-NS2B_R reverse CTCCTCTCTTTGTGTATTGGAGAGTTATC 256 WNV/PaRV-prME [CA] KUNV-NS3_F forward GATAACTCTCCAATACACAAAGAGAGGAG 257 WNV/PaRV-prME [CA] KUNV-NS2A_R reverse CTTCAGTTGCAGGCCACCC 258 WNV/PaRV-prME [CA] KUNV-NS2B_F forward GGGTGGCCTGCAACTGAAG 259 WNV/PaRV-prME [CA] KUNV-NS1_R reverse GAAAAGGATCAATCATGTCAGCGTTGTAG 260 WNV/PaRV-prME [CA] KUNV-NS2A_F forward CTACAACGCTGACATGATTGATCCTTTTC 261 WNV/PaRV-prME [CA] KUN-NS1-INT_R reverse CGGTCCATCCAAGCTTCCAC 262 WNV/PaRV-prME [CA] PE/KNS1_R reverse CACATCCAGTATCAGCTCGGGTATAAG 263 WNV/PaRV-prME [CA] PE/KNS1_F forward CTTATACCCGAGCTGATACTGGATGTG 264 WNV/PaRV-prME [CA] PE/KNS1.2_R reverse CCGACTTATATCTATGGCACATCCAGTATCAGCTCGGGTA 265 TAAGCGATTCCACAGAGGAT WNV/PaRV-prME [CA] PE/KNS1.2_F forward ATCCTCTGTGGAATCGCTTATACCCGAGCTGATACTGGAT 266 GTGCCATAGATATAAGTCGG WNV/PaRV-prME [CA] SwV qE-R reverse AAACATCCGGTTCCCCATCC 267 WNV/PaRV-prME [CA] SwV qE-F forward ATTCGACCGACATATGCCCC 268 WNV/PaRV-prME [CA] PaRV-C-prM-R_R reverse CCAAGAATGGCTCAACAAACTCACC 269 WNV/PaRV-prME [CA] PaRV-E_F forward GGTGAGTTTGTTGAGCCATTCTTGG 270 WNV/PaRV-prME [CA] KC/PPr_R reverse GGATTGTCACTGCTCCCACG 271 WNV/PaRV-prME [CA] KC/PPr_F forward CGTGGGAGCAGTGACAATCC 272 WNV/PaRV-prME [CA] KC/PPr2_R reverse ATCAGTAGTGACAACCACTTGGATTGTCACTGCTCCCACG 273 CCAGCAATCAAGCCAATCAT WNV/PaRV-prME [CA] KC/PPr2_F forward ATGATTGGCTTGATTGCTGGCGTGGGAGCAGTGACAATC 274 CAAGTGGTTGTCACTACTGAT WNV/PaRV-prME [CA] K/B(S)-C-SEQ_F forward CAGAAGAAGAGAGGAGGAAAGACC 275 WNV/PaRV-prME [CA] KUNV-5′UTR_R reverse GGCCCTCCTGGTTTCTTAGAC 276 WNV/PaRV-prME [CA] KUNV-C-prM_F forward GTCTAAGAAACCAGGAGGGCC 277 WNV/PaRV-prME [CA] KUNV-UTRlinker_R reverse CAGCTCACACAGGCGAACTACT 278 WNV/PaRV-prME [CA] KUNV-5′UTR_F forward AGTAGTTCGCCTGTGTGAGCTG 279 WNV/PaRV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 280 WNV/PaRV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 281 WNV/PaRV-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 282 WNV/PCV-prME [CA] KUNV-3′UTR_R reverse TCCTGTGTTCTCGCACCAC 283 WNV/PCV-prME [CA] KUNV-UTRlinker_F forward GTGGTGCGAGAACACAGGA 284 WNV/PCV-prME [CA] KUN-NS5(only)-R reverse TTACAATACTGTATCCTCAACCAATG 285 WNV/PCV-prME [CA] KUNV-NS5_R reverse CTGTATCCTCAACCAATGTTGTGTCTTC 286 WNV/PCV-prME [CA] KUNV-3′UTR_F forward GAAGACACAACATTGGTTGAGGATACAG 287 WNV/PCV-prME [CA] KUN-NS5(only)-F forward GGTGGGGCAAAAGGAC 288 WNV/PCV-prME [CA] KUNV-NS4B_R reverse CGTCCTTTTGCCCCACCTC 289 WNV/PCV-prME [CA] KUNV-NS5_F forward GAGGTGGGGCAAAAGGACG 290 WNV/PCV-prME [CA] KUNV-NS4A_R reverse CCCATCTCATTGGCTGCCAC 291 WNV/PCV-prME [CA] KUNV-NS4B_F forward GTGGCAGCCAATGAGATGGG 292 WNV/PCV-prME [CA] qWNns4A R reverse TAGCTGGTTGTCTGTCTGCG 293 WNV/PCV-prME [CA] qWNns4A F forward TTGAGTGTGATGACCATGGGAG 294 WNV/PCV-prME [CA] KUNV-NS3_R reverse GACCTCGATAAAACCTATTTGAGAGCGC 295 WNV/PCV-prME [CA] KUNV-NS4A_F forward GCGCTCTCAAATAGGTTTTATCGAGGTC 296 WNV/PCV-prME [CA] KUNV-NS2B_R reverse CTCCTCTCTTTGTGTATTGGAGAGTTATC 297 WNV/PCV-prME [CA] KUNV-NS3_F forward GATAACTCTCCAATACACAAAGAGAGGAG 298 WNV/PCV-prME [CA] KUNV-NS2A_R reverse CTTCAGTTGCAGGCCACCC 299 WNV/PCV-prME [CA] KUNV-NS2B_F forward GGGTGGCCTGCAACTGAAG 300 WNV/PCV-prME [CA] KUNV-NS1_R reverse GAAAAGGATCAATCATGTCAGCGTTGTAG 301 WNV/PCV-prME [CA] KUNV-NS2A_F forward CTACAACGCTGACATGATTGATCCTTTTC 302 WNV/PCV-prME [CA] KUN-NS1-INT_R reverse CGGTCCATCCAAGCTTCCAC 303 WNV/PCV-prME [CA] PCV-E/KUN-NS1_R reverse GGCACATCCAGTATCGGCTCGCACAAAATA 304 WNV/PCV-prME [CA] PCV-E/KUN-NS1_F forward TATTTTGTGCGAGCCGATACTGGATGTGCC 305 WNV/PCV-prME [CA] PCV-M_R reverse CGGTTCCATGTATTCTCCTCGAACCGTTGT 306 WNV/PCV-prME [CA] PCV-E_F forward ACAACGGTTCGAGGAGAATACATGGAACCG 307 WNV/PCV-prME [CA] KUN-C/PCV-Pr_R reverse GTCAATCACCACAACTGCTCCCACGCCAGC 308 WNV/PCV-prME [CA] KUN-C/PCV-Pr_F forward GCTGGCGTGGGAGCAGTTGTGGTGATTGAC 309 WNV/PCV-prME [CA] K/B(S)-C-SEQ_F forward CAGAAGAAGAGAGGAGGAAAGACC 310 WNV/PCV-prME [CA] KUNV-5′UTR_R reverse GGCCCTCCTGGTTTCTTAGAC 311 WNV/PCV-prME [CA] KUNV-C-prM_F forward GTCTAAGAAACCAGGAGGGCC 312 WNV/PCV-prME [CA] KUNV-UTRlinker_R reverse CAGCTCACACAGGCGAACTACT 313 WNV/PCV-prME [CA] KUNV-5′UTR_F forward AGTAGTTCGCCTGTGTGAGCTG 314 WNV/PCV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 315 WNV/PCV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 316 WNV/PCV-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 317 PCV/DENV2-prME [CA] PCV 3′-R reverse ATGCCATGCCGACCCAGACGTAGCCAAGTA 318 PCV/DENV2-prME [CA] PCV CA Linker-F forward TACTTGGCTACGTCTGGGTCGGCATGGCAT 319 PCV/DENV2-prME [CA] PCV NS5-R reverse CATCGTCACACTTCAGTTGAACACAGGATC 320 PCV/DENV2-prME [CA] PCV 3′-F forward GATCCTGTGTTCAACTGAAGTGTGACGATG 321 PCV/DENV2-prME [CA] PCV-NS5-INT_F forward CCGTATTTACCCAAAGGAGTGGAC 322 PCV/DENV2-prME [CA] PCV NS4B-R reverse ACTCTTCACCAGCGAGCGCACGCCCAATCT 323 PCV/DENV2-prME [CA] PCV NS5-F forward AGATTGGGCGTGCGCTCGCTGGTGAAGAGT 324 PCV/DENV2-prME [CA] PCV NS2B-R reverse TAGCTCCGAATTTGCCCGCTGGGACATAGC 325 PCV/DENV2-prME [CA] PCV NS3-F forward GCTATGTCCCAGCGGGCAAATTCGGAGCTA 326 PCV/DENV2-prME [CA] DENVE-PCV1_R reverse TCCACATCCGAAGTCGGCCTGCACCATAAC 327 PCV/DENV2-prME [CA] DENVE-PCV1_F forward GTTATGGTGCAGGCCGACTTCGGATGTGGA 328 PCV/DENV2-prME [CA] DENV2 M_R reverse TGCAGCGCATTGTCATTGAA 329 PCV/DENV2-prME [CA] DENV2 E_F forward TTCAATGACAATGCGCTGCA 330 PCV/DENV2-prME [CA] PCVC-DENVE_R reverse TGTGGTCAGATGAAATCCCATAACTCCGAA 331 PCV/DENV2-prME [CA] PCVC-DENVE_F forward TTCGGAGTTATGGGATTTCATCTGACCACA 332 PCV/DENV2-prME [CA] PCV-C-INT_R reverse CTCGCTTTTCCTCCTTGCTG 333 PCV/DENV2-prME [CA] PCV CA Linker-R reverse GCAAAAGTTTTTTAAAACTGTTTACCAGATCGTTGC 334 PCV/DENV2-prME [CA] PCV CA 5′-F forward GCAACGATCTGGTAAACAGTTTTAAAAAACTTTTGC 335 PCV/DENV2-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 336 PCV/DENV2-prME [CA] Op1E2-F forward CATTATAAGCTGCAATAAACAAGTT 337 PCV/DENV2-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 338 PCV/WNV-prME [CA] PCV 3′-R reverse ATGCCATGCCGACCCAGACGTAGCCAAGTA 339 PCV/WNV-prME [CA] PCV CA Linker-F forward TACTTGGCTACGTCTGGGTCGGCATGGCAT 340 PCV/WNV-prME [CA] PCV NS5-R reverse CATCGTCACACTTCAGTTGAACACAGGATC 341 PCV/WNV-prME [CA] PCV 3′-F forward GATCCTGTGTTCAACTGAAGTGTGACGATG 342 PCV/WNV-prME [CA] PCV-NS5-INT_F forward CCGTATTTACCCAAAGGAGTGGAC 343 PCV/WNV-prME [CA] PCV NS4B-R reverse ACTCTTCACCAGCGAGCGCACGCCCAATCT 344 PCV/WNV-prME [CA] PCV NS5-F forward AGATTGGGCGTGCGCTCGCTGGTGAAGAGT 345 PCV/WNV-prME [CA] PCV NS2B-R reverse TAGCTCCGAATTTGCCCGCTGGGACATAGC 346 PCV/WNV-prME [CA] PCV NS3-F forward GCTATGTCCCAGCGGGCAAATTCGGAGCTA 347 PCV/WNV-prME [CA] KUNE-PCV1-R reverse TCCACATCCGAAGTCAGCATGCACGTTCAC 348 PCV/WNV-prME [CA] KUNE-PCV1-F forward GTGAACGTGCATGCTGACTTCGGATGTGGA 349 PCV/WNV-prME [CA] KUN-E-Seq-F forward GCATGGACCAACTACCG 350 PCV/WNV-prME [CA] KUNV-C-prM_R reverse GGAAATCTCTGTTGCTCATTCCAAGACAG 351 PCV/WNV-prME [CA] KUNV-E_F forward CTGTCTTGGAATGAGCAACAGAGATTTCC 352 PCV/WNV-prME [CA] PCVC-KUNVpr-R reverse GTTGGAGAGAGTGACTCCCATAACTCCGAA 353 PCV/WNV-prME [CA] PCVC-KUNVpr-F forward TTCGGAGTTATGGGAGTCACTCTCTCCAAC 354 PCV/WNV-prME [CA] PCV-C-INT_R reverse CTCGCTTTTCCTCCTTGCTG 355 PCV/WNV-prME [CA] PCV CA Linker-R reverse GCAAAAGTTTTTTAAAACTGTTTACCAGATCGTTGC 356 PCV/WNV-prME [CA] PCV CA 5′-F forward GCAACGATCTGGTAAACAGTTTTAAAAAACTTTTGC 357 PCV/WNV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 358 PCV/WNV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 359 PCV/WNV-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 360 PCV/ZIKV-prME [CA] PCV 3′-R reverse ATGCCATGCCGACCCAGACGTAGCCAAGTA 361 PCV/ZIKV-prME [CA] PCV CA Linker-F forward TACTTGGCTACGTCTGGGTCGGCATGGCAT 362 PCV/ZIKV-prME [CA] PCV NS5-R reverse CATCGTCACACTTCAGTTGAACACAGGATC 363 PCV/ZIKV-prME [CA] PCV 3′-F forward GATCCTGTGTTCAACTGAAGTGTGACGATG 364 PCV/ZIKV-prME [CA] PCV-NS5-INT_F forward CCGTATTTACCCAAAGGAGTGGAC 365 PCV/ZIKV-prME [CA] PCV NS4B-R reverse ACTCTTCACCAGCGAGCGCACGCCCAATCT 366 PCV/ZIKV-prME [CA] PCV NS5-F forward AGATTGGGCGTGCGCTCGCTGGTGAAGAGT 367 PCV/ZIKV-prME [CA] PCV NS2B-R reverse TAGCTCCGAATTTGCCCGCTGGGACATAGC 368 PCV/ZIKV-prME [CA] PCV NS3-F forward GCTATGTCCCAGCGGGCAAATTCGGAGCTA 369 PCV/ZIKV-prME [CA] ZIKVE-PCV1_R reverse TCCACATCCGAAGTCAGCAGAGACGGCTGT 370 PCV/ZIKV-prME [CA] ZIKVE-PCV1_F forward ACAGCCGTCTCTGCTGACTTCGGATGTGGA 371 PCV/ZIKV-prME [CA] Zika M_R reverse TGCACCTGATGCTGTATGCC 372 PCV/ZIKV-prME [CA] Zika E_F forward GGCATACAGCATCAGGTGCA 373 PCV/ZIKV-prME [CA] PCVC-ZIKVPr_R reverse TCTAGTGACCTCCGCTCCCATAACTCCGAA 374 PCV/ZIKV-prME [CA] PCVC-ZIKVPr_F forward TTCGGAGTTATGGGAGCGGAGGTCACTAGA 375 PCV/ZIKV-prME [CA] PCV-C-INT_R reverse CTCGCTTTTCCTCCTTGCTG 376 PCV/ZIKV-prME [CA] PCV CA Linker-R reverse GCAAAAGTTTTTTAAAACTGTTTACCAGATCGTTGC 377 PCV/ZIKV-prME [CA] PCV CA 5′-F forward GCAACGATCTGGTAAACAGTTTTAAAAAACTTTTGC 378 PCV/ZIKV-prME [CA] pUC19-R reverse TGGATGGCCTTCCCCATTAT 379 PCV/ZIKV-prME [CA] OplE2-F forward CATTATAAGCTGCAATAAACAAGTT 380 PCV/ZIKV-prME [CA] DNA Linker-F forward GGGTCGGCATGGCATCTCC 381

(562) TABLE-US-00002 TABLE 2 Binding profiles of a panel of 9 mAbs to epitopes on WNV prM, and all 3 domains of the WNV E protein (including quaternary prM/E epitopes) confirm that PCV/WNV.sub.KUN-prME and BinJV/WNV.sub.KUN- prME particles are antigenically identical to WNV in these regions. Data also demonstrates that cross-reactive mAbs to the fusion loop in the EII domain and a quaternary prM/E epitope, fail to bind to BinJV due to a Valine at residue 106 in the wild type virus. Anti-WNV mAb reactivity Virus/mAb prM + E prM EDI EDII EDIII NS1 target M2-1E7 P10F8 17D7 4G2 6B6C1 P3H8 3.91D 2B2 3.67G 3.1112G WNV + + + + + + + + + + PCV- + + + + + + + + + − WNV.sub.STR* BinJV- + + + + + + + + + − WNV.sub.STR.sup.# PCV − − − − − − − − − − BinJV − − − − − − − − − − BinJV.sub.V106G + − − + + + − − − −

(563) TABLE-US-00003 TABLE 3 Binding profiles of a panel of 5 mAbs to epitopes on ZIKV E protein confirm that PCV/ZIKV-prME particles are antigenically identical to ZIKV in these regions. Anti-ZIKV mAb reactivity Virus/mAb EDII EDIII NS1 target 5G12 4G2 6B6C1 P3H8 4A4 3H3 2G1 ZIKV + + + + + + + PCV- + + + + + − − ZIKV.sub.STR*